U.S. patent application number 16/950357 was filed with the patent office on 2021-03-04 for process for the production of cannabidiol and delta-9-tetrahydrocannabinol.
The applicant listed for this patent is PURISYS, LLC. Invention is credited to Lukas Dialer, Denis Petrovic, Ulrich Weigl.
Application Number | 20210061781 16/950357 |
Document ID | / |
Family ID | 1000005220197 |
Filed Date | 2021-03-04 |
View All Diagrams
United States Patent
Application |
20210061781 |
Kind Code |
A1 |
Dialer; Lukas ; et
al. |
March 4, 2021 |
PROCESS FOR THE PRODUCTION OF CANNABIDIOL AND
DELTA-9-TETRAHYDROCANNABINOL
Abstract
The present disclosure relates to the preparation of a
cannabidiol compound or a derivative thereof. The cannabidiol
compound or derivatives thereof can be prepared by an
acid-catalyzed reaction of a suitably selected and substituted
di-halo-olivetol or derivative thereof with a suitably selected and
substituted cyclic alkene to produce a dihalo-cannabidiol compound
or derivative thereof. The dihalo-cannabidiol compound or
derivative thereof can be produced in high yield, high
stereospecificity, or both. It can then be converted under reducing
conditions to a cannabidiol compound or derivatives thereof.
Inventors: |
Dialer; Lukas;
(Schaffhausen, CH) ; Petrovic; Denis;
(Schaffhausen, CH) ; Weigl; Ulrich; (Schaffhausen,
CH) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
PURISYS, LLC |
Athens |
GA |
US |
|
|
Family ID: |
1000005220197 |
Appl. No.: |
16/950357 |
Filed: |
November 17, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16034876 |
Jul 13, 2018 |
10844035 |
|
|
16950357 |
|
|
|
|
15199528 |
Jun 30, 2016 |
10059683 |
|
|
16034876 |
|
|
|
|
62191097 |
Jul 10, 2015 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 311/04 20130101;
C07C 37/11 20130101; C07D 205/04 20130101; C07C 37/14 20130101;
C07D 311/80 20130101; C07D 311/78 20130101 |
International
Class: |
C07D 311/78 20060101
C07D311/78; C07D 205/04 20060101 C07D205/04; C07C 37/14 20060101
C07C037/14; C07D 311/04 20060101 C07D311/04; C07C 37/11 20060101
C07C037/11; C07D 311/80 20060101 C07D311/80 |
Claims
1.-20. (canceled)
21. A composition comprising a compound of formula (XVI):
##STR00082## or a pharmaceutically acceptable salt thereof, wherein
said composition comprises at least 99.96 area % of the compound of
formula (XVI) and less than 0.04 area % of
4,6-dihalo-5-pentylbenzene-1,3-diol,
4-halo-5-pentylbenzene-1,3-diol, 6-halo-5-pentylbenzene-1,3-diol,
and delta-9-tetrahydrocannabinol.
22. The composition of claim 21, wherein said composition is a
white crystalline powder.
23. The composition of claim 21, wherein said halo is chloro or
bromo.
24. The composition of claim 23, wherein said halo is bromo.
25. The composition of claim 24, comprising a compound of formula
(XVI): ##STR00083## or a pharmaceutically acceptable salt thereof,
wherein said composition comprises at least 99.96 area % of the
compound of formula (XVI) and less than 0.04 area % of
4-bromo-5-pentylbenzene-1,3-diol, 6-bromo-5-pentylbenzene-1,3-diol,
and delta-9-tetrahydrocannabinol.
26. The composition of claim 21, wherein said compound of formula
(XVI) has an enantiomeric excess of at least about 99%.
27. A composition comprising a compound of formula (XVI):
##STR00084## or a pharmaceutically acceptable salt thereof; wherein
said composition comprises no more than 400 ppm of
4,6-dihalo-5-pentylbenzene-1,3-diol,
4-halo-5-pentylbenzene-1,3-diol, 6-halo-5-pentylbenzene-1,3-diol,
and delta-9-tetrahydrocannabinol.
28. The composition of claim 27, wherein said halo is chloro or
bromo.
29. The composition of claim 28, wherein said halo is bromo.
30. The composition of claim 29, comprising no more than 400 ppm of
4-bromo-5-pentylbenzene-1,3-diol, 6-bromo-5-pentylbenzene-1,3-diol,
and delta-9-tetrahydrocannabinol
31. The composition of claim 27, wherein said composition is a
white crystalline powder.
32. The composition of claim 27, wherein said compound of formula
(XVI) has an enantiomeric excess of at least about 99%.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional of U.S. patent application
Ser. No. 16/034,876 filed Jul. 13, 2018, which is a continuation of
U.S. patent application Ser. No. 15/199,528 filed Jun. 30, 2016,
and now U.S. Pat. No. 10,059,683 issued on Aug. 28, 2018, which
claims the benefit of and priority to U.S. Provisional Patent
Application No. 62/191,097, filed on Jul. 10, 2015, the entire
contents of which are incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The present disclosure relates to the preparation of a
cannabidiol compound or a derivative thereof. The cannabidiol
compound or derivative thereof can be prepared by an acid-catalyzed
reaction of a suitably selected and substituted di-halo-olivetol or
derivative thereof with a suitably selected and substituted cyclic
alkene to produce a dihalo-cannabidiol compound or derivative
thereof. The dihalo-cannabidiol compound or derivative thereof can
be produced in high yield, high stereospecificity, or both. It can
then be converted under reducing conditions to a cannabidiol
compound or derivatives thereof.
BACKGROUND OF THE INVENTION
[0003] More than 100 phytocannabinoids have been isolated to date.
See Pertwee, et al. "Hand book of Cannabis," Oxford University
Press, First Edition 2014, ISBN 978-0-19-966268-5.
Phytocannabinoids are cannabinoids that originate from nature and
can be found in the cannabis plant. These compounds have been
investigated based, in part, on their availability from a natural
source. The term "cannabinoids" generally refers to not only the
chemical substances isolated from C. sativa L exhibiting the
typical C21 terpenophilic skeleton, but also to their derivatives
and transformation products.
[0004] In addition to the historical and anecdotal medicinal use of
cannabinoids, the FDA has approved cannabinoid based products, such
as Marinol.TM. and a number of other regulatory agencies have
approved Sativex.TM.. Many other cannabinoids are being
investigated by the mainstream pharmaceutical industry for various
indications. Examples of cannabinoids either approved for clinical
use or in clinical trials include Epidiolex.TM. (e.g., cannabidiol)
for Dravet Syndrome and Lennox-Gastaut Syndrome; cannabidivarin for
epilepsy; and tetrahydrocannabidivarin for diabetes.
[0005] Many different routes to produce cannabinoids and related
compounds have been reported. One route involves variations on the
Lewis-acid catalyzed Friedel Crafts alkylation of olivetol with
menthadienol. For example, U.S. Pat. No. 5,227,537 describes a
reaction of equimolar quantities of olivetol and menthadienol in
the presence of p-toluenesulfonic acid catalyst which resulted in a
44% yield of cannabidiol after purification by column
chromatography. U.S. Pat. No. 7,674,922 describes a similar
reaction using a Lewis acid catalyst instead of p-toluenesulfonic
acid which results in the formation of significant amounts of the
unwanted cannabidiol isomer along with cannabidiol. The reaction
route described in the '922 patent resulted in a 47% yield of the
desired cannabidiol, a 17.9% yield of the abn cannabidiol and 23%
of unreacted olivetol.
[0006] In addition, U.S. Pat. No. 3,562,312 describes improved
selectivity for the formation of cannabidiol by reacting
6-carbethoxyolivetol with a slight excess of menthadienol in
methylene chloride in the presence of dimethylformamide,
dineopentylacetal as catalyst. This route resulted in a 42% yield
of cannabidiol-carboxylic acid ethyl ester after purification by
chromatography.
[0007] Another route for the preparation of cannabidiols involves
the use of carboxylic acid esters as protecting/directing groups on
olivetol analogues. See, e.g., Crombie, L. et al., in J. Chem.
Research (S) 114, (M), pp 1301-1345 (1977). In a first step,
alkylresorcyl esters (e.g., 6-alkyl-2,4-di-hydroxybenzoic esters)
are condensed with unsaturated hydrocarbons, alcohols, ketones, or
derivatives thereof such as enol esters, enol ethers and ketals, in
high yields to give the corresponding 3-substituted
6-alkyl-2,4-dihydroxybenzoic esters. These routes of preparation
have been referred to as acid-catalyzed terpenylation. In a second
step, the intermediates with an ester function obtained in the
first step are subjected to a decarboxylating hydrolysis, which
forms the ester-free cannabinoids.
[0008] For example, improvements in selectivity have been achieved
by protecting the 4 position of the olivetol related compounds with
a carboxylic acid ester. The '922 patent describes the preparation
of ethyl cannabidiolate in 82% yield and 93.3% (AUC) purity. After
NaOH hydrolysis, however, the route resulted in a 57.5% yield and
99.8% purity (AUC). The '922 patent also describes the need to
purify the cannabidiols formed, e.g.,
.DELTA.-9-tetrahydrocannabinol, by esterification of the free
hydroxyl followed by purification of the cannabidiol ester, e.g.,
.DELTA.-9-tetrahydrocannabinol ester. Purification was performed by
crystallization followed by hydrolysis of the ester to the
.DELTA.-9-tetrahydrocannabinol. Such steps were required to achieve
a purity necessary for pharmaceutical use.
[0009] The prior art demonstrates the difficulties of manufacturing
cannabidiol compounds or derivatives thereof, e.g.,
.DELTA.-9-tetrahydrocannabinol, in high yield, high
stereospecificity, or both. The causes of these difficulties can
include the non-crystalline nature of the materials which renders
them difficult or impossible to separate and purify without
chromatography. Also, the aromatic portion of the cannabidiol
molecule is sensitive to oxidation. And, in one specific example,
the thermodynamic stability of the .DELTA.-9-unsaturation relative
to .DELTA.-8-unsaturation favors the formation of .DELTA.-8
derivatives.
[0010] The present disclosure relates to the preparation of a
cannabidiol compound or a derivative thereof using a simple
synthesis route to produce a cannabidiol compound or derivative
thereof in high yield, high stereospecificity, or both.
SUMMARY OF THE INVENTION
[0011] The present disclosure relates to the preparation of a
cannabidiol compound or a derivative thereof. The cannabidiol
compound or derivative thereof can be prepared by an acid-catalyzed
reaction of a suitably selected and substituted di-halo-olivetol or
derivative thereof with a suitably selected and substituted cyclic
alkene (e.g., a cyclic alkene containing a 1-methyl-1-ethenyl
substituent) to produce a dihalo-cannabidiol compound or derivative
thereof. The dihalo-cannabidiol compound or derivative thereof can
be produced in high yield, high stereospecificity, or both. It can
then be converted under reducing conditions to a cannabidiol
compound or derivative thereof.
[0012] The present disclosure also relates to the preparation of a
.DELTA.-9-tetrahydrocannabinol compound or derivative thereof. The
.DELTA.-9-tetrahydrocannabinol compound or derivative thereof can
be prepared by an acid-catalyzed reaction of a suitably selected
and substituted di-halo-olivetol or derivative thereof with a
suitably selected and substituted cyclic alkene to produce a
dihalo-cannabidiol compound or derivative thereof. The
dihalo-cannabidiol compound or derivative thereof can be produced
in high yield, high stereospecificity, or both. It can then be
reacted with a Lewis acid catalyst to produce a
dihalo-.DELTA.-9-tetrahydrocannabinol compound or derivative
thereof. The dihalo-.DELTA.-9-tetrahydrocannabinol compound or
derivative thereof can then be converted under reducing conditions
to a .DELTA.-9-tetrahydrocannabinol compound or derivative thereof.
Alternatively, the reduction and cyclization steps can be performed
in reverse order.
[0013] In one embodiment, the present disclosure relates to a
process for the preparation of a compound of formula (I)
##STR00001##
[0014] wherein a is an integer from 0 to 3;
[0015] R.sup.1 and R.sup.2 are each independently selected from the
group consisting of H, OH, protected hydroxyl, alkyl, alkenyl,
alkynyl, acyl, aryl, heteroaryl, cycloalkyl or heterocycle;
[0016] wherein the alkyl, alkenyl, alkynyl or acyl is optionally
substituted with one or more substituents independently selected
from the group consisting of halogen, --OH, alkyl, --O-alkyl,
NR.sup.AR.sup.B, --S-alkyl, --SO-alkyl, --SO.sub.2-alkyl, alkenyl,
alkynyl, aryl, heteroaryl, cycloalkyl or heterocycle; wherein
R.sup.A and R.sup.B are each independently selected from hydrogen
and C.sub.1-4 alkyl;
[0017] wherein the aryl or heteroaryl, whether alone or as part of
a substituent group, is optionally substituted with one or more
substituents independently selected from the group consisting of
halogen, --OH, alkyl, --O-alkyl, --COOH, --C(O)--C.sub.1-4 alkyl,
--C(O)O--C.sub.1-4 alkyl, NR.sup.CR.sup.D, --S-alkyl, --SO-alkyl
and --SO.sub.2-alkyl; wherein R.sup.C and R.sup.D are each
independently selected from hydrogen and C.sub.1-4 alkyl;
[0018] R.sup.3 is selected from the group consisting of H, alkyl,
acyl, --SO.sub.2-alkyl, --SO.sub.2-aryl and --SO.sub.2-heteroaryl;
wherein the alkyl is optionally substituted with one or more
substituents independently selected from the group consisting of
halogen, --OH, alkyl, --O-alkyl, NR.sup.ER.sup.F, --S-alkyl,
--SO-alkyl, --SO.sub.2-alkyl, aryl and heteroaryl; and wherein
R.sup.E and R.sup.F are each independently selected from hydrogen
and C.sub.1-4 alkyl; wherein the aryl or heteroaryl, whether alone
or as part of a substituent group, is optionally substituted with
one or more substituents independently selected from the group
consisting of halogen, --OH, alkyl, --O-alkyl, NR.sup.GR.sup.H,
--S-alkyl, --SO-alkyl and --SO.sub.2-alkyl; wherein R.sup.G and
R.sup.H are each independently selected from hydrogen and C.sub.1-4
alkyl;
[0019] each represents a single or double bond; provided that both
groups are not double bonds, and wherein denoted, dash marks
indicate the points of attachment,
[0020] or a pharmaceutically acceptable salt or ester thereof;
[0021] the process including reacting a compound of formula (II),
wherein each X is independently selected from the group consisting
of Br, F, I and Cl, with a compound of formula (III) wherein
R.sup.0 is H or OH, in the presence of a protic or first Lewis acid
catalyst to form a compound of formula (IV);
##STR00002##
[0022] cyclizing the compound of formula (IV) by reacting the
compound of formula (IV) with a second Lewis acid catalyst to form
a compound of formula (V); and
##STR00003##
[0023] reacting the compound of formula (V) with a reducing agent
to form the compound of formula (I)
##STR00004##
[0024] In another embodiment, the present disclosure relates to a
process for the preparation of a compound of formula (I)
##STR00005##
[0025] wherein a is an integer from 0 to 3;
[0026] R.sup.1 and R.sup.2 are each independently selected from the
group consisting of H, OH, protected hydroxyl, alkyl, alkenyl,
alkynyl, acyl, aryl, heteroaryl, cycloalkyl or heterocycle;
[0027] wherein the alkyl, alkenyl, alkynyl or acyl is optionally
substituted with one or more substituents independently selected
from the group consisting of halogen, --OH, alkyl, --O-alkyl,
NR.sup.AR.sup.B, --S-alkyl, --SO-alkyl, --SO.sub.2-alkyl, alkenyl,
alkynyl, aryl, heteroaryl, cycloalkyl or heterocycle; wherein
R.sup.A and R.sup.B are each independently selected from hydrogen
and C.sub.1-4 alkyl;
[0028] wherein the aryl or heteroaryl, whether alone or as part of
a substituent group, is optionally substituted with one or more
substituents independently selected from the group consisting of
halogen, --OH, alkyl, --O-alkyl, --COOH, --C(O)--C.sub.1-4 alkyl,
--C(O)O--C.sub.1-4 alkyl, NR.sup.CR.sup.D, --S-alkyl, --SO-alkyl
and --SO.sub.2-alkyl; wherein R.sup.C and R.sup.D are each
independently selected from hydrogen and C.sub.1-4 alkyl;
[0029] R.sup.3 is selected from the group consisting of H, alkyl,
acyl, --SO.sub.2-alkyl, --SO.sub.2-aryl and --SO.sub.2-heteroaryl;
wherein the alkyl is optionally substituted with one or more
substituents independently selected from the group consisting of
halogen, --OH, alkyl, --O-alkyl, NR.sup.ER.sup.F, --S-alkyl,
--SO-alkyl, --SO.sub.2-alkyl, aryl and heteroaryl; and wherein
R.sup.E and R.sup.F are each independently selected from hydrogen
and C.sub.1-4 alkyl; wherein the aryl or heteroaryl, whether alone
or as part of a substituent group, is optionally substituted with
one or more substituents independently selected from the group
consisting of halogen, --OH, alkyl, --O-alkyl, NR.sup.GR.sup.H,
--S-alkyl, --SO-alkyl and --SO.sub.2-alkyl; wherein R.sup.G and
R.sup.H are each independently selected from hydrogen and C.sub.1-4
alkyl;
[0030] each represents a single or double bond; provided that both
groups are not double bonds, and wherein denoted, dash marks
indicate the points of attachment;
[0031] or a pharmaceutically acceptable salt or ester thereof;
[0032] the process including reacting a compound of formula (II),
wherein each X is independently selected from the group consisting
of Br, F, I and Cl, with a compound of formula (III) wherein
R.sup.0 is H or OH in the presence of a protic or first Lewis acid
catalyst to form a compound of formula (IV);
##STR00006##
[0033] reacting the compound of formula (IV) with a reducing agent
to form a compound of formula (VI); and
##STR00007##
[0034] cyclizing the compound of formula (VI) by reacting the
compound of formula (VI) with a second Lewis acid catalyst to form
the compound of formula (I).
##STR00008##
[0035] In another embodiment, the present disclosure relates to a
process for the preparation of a compound of formula (VI)
##STR00009##
[0036] wherein a is an integer from 0 to 3;
[0037] R.sup.1 and R.sup.2 are each independently selected from the
group consisting of H, OH, protected hydroxyl, alkyl, alkenyl,
alkynyl, acyl, aryl, heteroaryl, cycloalkyl or heterocycle;
[0038] wherein the alkyl, alkenyl, alkynyl or acyl is optionally
substituted with one or more substituents independently selected
from the group consisting of halogen, --OH, alkyl, --O-alkyl,
NR.sup.AR.sup.B, --S-alkyl, --SO-alkyl, --SO.sub.2-alkyl, alkenyl,
alkynyl, aryl, heteroaryl, cycloalkyl or heterocycle; wherein
R.sup.A and R.sup.B are each independently selected from hydrogen
and C.sub.1-4 alkyl;
[0039] wherein the aryl or heteroaryl, whether alone or as part of
a substituent group, is optionally substituted with one or more
substituents independently selected from the group consisting of
halogen, --OH, alkyl, --O-alkyl, --COOH, --C(O)--C.sub.1-4 alkyl,
--C(O)O--C.sub.1-4 alkyl, NR.sup.CR.sup.D, --S-alkyl, --SO-alkyl
and --SO.sub.2-alkyl; wherein R.sup.C and R.sup.D are each
independently selected from hydrogen and C.sub.1-4 alkyl;
[0040] R.sup.3 is selected from the group consisting of H, alkyl,
acyl, --SO.sub.2-alkyl, --SO.sub.2-aryl and --SO.sub.2-heteroaryl;
wherein the alkyl is optionally substituted with one or more
substituents independently selected from the group consisting of
halogen, --OH, alkyl, --O-alkyl, NR.sup.ER.sup.F, --S-alkyl,
--SO-alkyl, --SO.sub.2-alkyl, aryl and heteroaryl; and wherein
R.sup.E and R.sup.F are each independently selected from hydrogen
and C.sub.1-4 alkyl; wherein the aryl or heteroaryl, whether alone
or as part of a substituent group, is optionally substituted with
one or more substituents independently selected from the group
consisting of halogen, --OH, alkyl, --O-alkyl, NR.sup.GR.sup.H,
--S-alkyl, --SO-alkyl and --SO.sub.2-alkyl; wherein R.sup.G and
R.sup.H are each independently selected from hydrogen and C.sub.1-4
alkyl;
[0041] each represents a single or double bond; provided that both
groups are not double bonds, and wherein denoted, dash marks
indicate the points of attachment;
[0042] or a pharmaceutically acceptable salt or ester thereof;
[0043] the process including reacting a compound of formula (II),
wherein each X is independently selected from the group consisting
of Br, F, I and Cl, with a compound of formula (III) wherein
R.sup.0 is H or OH, in the presence of a protic or first Lewis acid
catalyst to form a compound of formula (IV); and
##STR00010##
[0044] reacting the compound of formula (IV) with a reducing agent
to form the compound of formula (VI)
##STR00011##
[0045] In another embodiment, the present disclosure relates to a
process for the preparation of a compound of formula (XI)
##STR00012##
[0046] or a pharmaceutically acceptable salt or ester thereof;
[0047] the process including reacting a compound of formula (XII),
wherein each X is independently selected from Br, F, I or Cl, with
a compound of formula (XIII) in the presence of a protic or first
Lewis acid catalyst to form a compound of formula (XIV);
##STR00013##
[0048] cyclizing the compound of formula (XIV) by reacting the
compound of formula (XIV) with a second Lewis acid catalyst to form
a compound of formula (XV); and
##STR00014##
[0049] reacting the compound of formula (XV) with a reducing agent
to form the compound of formula (XI)
##STR00015##
[0050] In another embodiment, the present disclosure relates to a
process for the preparation of a compound of formula (XI)
##STR00016##
[0051] or a pharmaceutically acceptable salt or ester thereof;
[0052] the process including reacting a compound of formula (XII),
wherein each X is independently selected from Br, F, I or Cl, with
a compound of formula (XIII) in the presence of a protic or first
Lewis acid catalyst to for a compound of formula (XIV)
##STR00017##
[0053] reacting the compound of formula (XIV) with a reducing agent
to for a compound of formula (XVI); and
##STR00018##
[0054] cyclizing the compound of formula (XVI) by reacting the
compound of formula (XVI) with a second Lewis acid catalyst to form
the compound of formula (XI)
##STR00019##
[0055] In another embodiment, the present disclosure relates to a
process for the preparation of a compound of formula (XVI)
##STR00020##
[0056] or a pharmaceutically acceptable salt or ester thereof;
[0057] the process including reacting a compound of formula (XII),
wherein each X is independently selected from Br, F, I or Cl, with
a compound of formula (XIII) in the presence of a protic or first
Lewis acid catalyst to form a compound of formula (XIV); and
##STR00021##
[0058] reacting the compound of formula (XIV) with a reducing agent
to form the compound of formula (XVI)
##STR00022##
[0059] In the processes described above, the formed compounds can
be a cannibidiol or related compound. In particular, the compound
of formula (I) can be ethyl cannabidiolate,
delta-9-tetrahydrocannabidiol or delta-8-tetrahydrocannabidiol. In
particular, the compound of formula (IV) can be cannibidiol,
cannabidivarin or
1-(3-(((1'R,2'R)-2,6-dihydroxy-5'-methyl-2'-(prop-1-en-2-yl)-1',2',3',4'--
tetrahydro-[1,1'-biphenyl]-4-yl)methyl)azetidin-1-yl)ethan-1-one
(depicted below)
##STR00023##
[0060] The processes of the present disclosure provide a number of
advantages over current methods. As described in the prior art, the
Lewis acid catalyzed condensation of olivetol or olivetolate esters
with menthadienol to prepare cannabidiol or cannibidiolate esters
suffers from poor selectivity resulting low yields and mixtures of
isomers requiring tedious purification procedures. For example, the
use of boron trifluoride etherate results in uncontrolled
conversion of cannabidiol and the cyclization of
.DELTA.-9-tetrahydrocannabinol to .DELTA.-8-tetrahydrocannabinol.
In the present disclosure, one or both of the 4 and 6 positions of
olivetol or derivatives thereof can be blocked with a halogen
selected from the group consisting of Br, F, I and Cl. In
particular, both positions can be blocked with a halogen selected
from the group consisting of Br, F, I and Cl. In one embodiment,
both positions can be blocked with a Br. In another embodiment,
both positions can be blocked with a F. In yet another embodiment,
both positions can be blocked with a Cl. The position can be
blocked to control the conversion and prevent the formation of
unwanted cannabidiol isomers, such as the abn cannabidiol. In
addition, the process can be designed, such as by using excess
equivalents of an alkene relative to a halogen substituted olivetol
or derivatives thereof to form the corresponding halogen
substituted cannabidiol or derivative thereof in a high yield, high
selectivity or both. In some embodiments, deficient amount can be
used for economical purposes. The halogen substituted cannabidiol
can also remain stable and not undergo uncontrolled conversion to
one or more cyclized products. The halogen substituted cannabidiol
or derivative thereof can also be easily converted to a cannabidiol
or derivative thereof by reacting with a suitably selected reducing
agent, under mild conditions, to yield the desired product in high
yield, high purity or both.
[0061] The processes of the present disclosure can achieve high
yield, high purity or both without the need to use organo-aluminum
Lewis acid catalysts. The processes of the present disclosure can
use a wide selection of catalysts including boron trifluoride
etherate and aluminum trichloride. The processes of the present
disclosure can achieve high yield, high purity cannabinoid or
derivative, or both without the need for purification by formation
of a polar ester group, crystallization of the resulting ester,
and/or hydrolysis to purified cannabidiol or related derivative, or
related purification. The processes of the present disclosure do
not require additional derivatization of the isolated cannabidiol
or related derivative, e.g., .DELTA.-9-tetrahydrocannabinol, prior
to pharmaceutical use.
BRIEF DESCRIPTION OF THE DRAWINGS
[0062] The foregoing and other advantages provided by the present
disclosure will be more fully understood from the following
description of exemplary embodiments when read together with the
accompanying drawings, in which:
[0063] FIG. 1 shows exemplary synthetic pathways of the present
disclosure.
[0064] FIG. 2 shows an exemplary synthesis of
delta-9-tetrahydrocannabidiol.
[0065] FIG. 3 shows another exemplary synthesis of
delta-9-tetrahydrocannabidiol.
[0066] FIG. 4 shows an exemplary synthesis of a C.sub.3-olivetol
analogue starting from 3,5-dimethoxybenzoic acid.
[0067] FIG. 5 shows exemplary synthetic pathways for the
C3-cannabidiol and C3-tetrahydrocannabinol analogues using bromide
protective groups.
[0068] FIG. 6 shows an exemplary synthetic pathway for cannabidiol
using chloride protective groups.
[0069] FIG. 7 shows an exemplary synthetic pathway for cannabidiol
using iodide protective groups.
[0070] FIG. 8 shows exemplary olefins used in coupling reactions
with dibromo-olivetol.
[0071] FIG. 9 shows the structure of dibromo-olivetol coupled with
cyclohex-2-enol.
DETAILED DESCRIPTION OF THE INVENTION
[0072] The present disclosure relates to processes for the
preparation of a cannabidiol compound or derivatives thereof. For
example, the present disclosure relates to processes for the
preparation of cannabidiol, .DELTA.-9-tetrahydrocannabinol,
cannabidiolic acid, .DELTA.-9-tetrahydrocannabinolic acid,
intermediate compounds thereof and derivative compounds
thereof.
[0073] In an embodiment, the present disclosure is directed to
process(es) for the preparation of a compound of formula (I) or
pharmaceutically acceptable salt or ester thereof.
[0074] In one embodiment, the present disclosure relates to a
process for the preparation of a compound of formula (I)
##STR00024##
[0075] wherein a is an integer from 0 to 3 (e.g., forming a 5, 6, 7
or 8 membered ring);
[0076] R.sup.1 and R.sup.2 are each independently selected from the
group consisting of H, OH, protected hydroxyl, alkyl, alkenyl,
alkynyl, acyl, aryl, heteroaryl, cycloalkyl or heterocycle;
[0077] wherein the alkyl, alkenyl, alkynyl or acyl is optionally
substituted with one or more substituents independently selected
from the group consisting of halogen, --OH, alkyl, --O-alkyl,
NR.sup.AR.sup.B, --S-alkyl, --SO-alkyl, --SO.sub.2-alkyl, alkenyl,
alkynyl, aryl, heteroaryl, cycloalkyl or heterocycle; wherein
R.sup.A and R.sup.B are each independently selected from hydrogen
and C.sub.1-4 alkyl;
[0078] wherein the aryl or heteroaryl, whether alone or as part of
a substituent group, is optionally substituted with one or more
substituents independently selected from the group consisting of
halogen, --OH, alkyl, --O-alkyl, --COOH, --C(O)--C.sub.1-4 alkyl,
--C(O)O--C.sub.1-4 alkyl, NR.sup.CR.sup.D, --S-alkyl, --SO-alkyl
and --SO.sub.2-alkyl; wherein R.sup.C and R.sup.D are each
independently selected from hydrogen and C.sub.1-4 alkyl;
[0079] R.sup.3 is selected from the group consisting of H, alkyl,
acyl, --SO.sub.2-alkyl, --SO.sub.2-aryl and --SO.sub.2-heteroaryl;
wherein the alkyl is optionally substituted with one or more
substituents independently selected from the group consisting of
halogen, --OH, alkyl, --O-alkyl, NR.sup.ER.sup.F, --S-alkyl,
--SO-alkyl, --SO.sub.2-alkyl, aryl and heteroaryl; and wherein
R.sup.E and R.sup.F are each independently selected from hydrogen
and C.sub.1-4 alkyl; wherein the aryl or heteroaryl, whether alone
or as part of a substituent group, is optionally substituted with
one or more substituents independently selected from the group
consisting of halogen, --OH, alkyl, --O-alkyl, NR.sup.GR.sup.H,
--S-alkyl, --SO-alkyl and --SO.sub.2-alkyl; wherein R.sup.G and
R.sup.H are each independently selected from hydrogen and C.sub.1-4
alkyl;
[0080] each represents a single or double bond; provided that both
groups are not double bonds, and wherein denoted, dash marks
indicate the points of attachment;
[0081] or a pharmaceutically acceptable salt or ester thereof;
[0082] the process including reacting a compound of formula (II),
wherein each X is independently selected from the group consisting
of Br, F, I and Cl, with a compound of formula (III) wherein
R.sup.0 is H or OH (or as otherwise defined herein), in the
presence of a protic or first Lewis acid catalyst to form a
compound of formula (IV);
##STR00025##
[0083] cyclizing the compound of formula (IV) by reacting the
compound of formula (IV) with a second Lewis acid catalyst to form
a compound of formula (V); and
##STR00026##
[0084] reacting the compound of formula (V) with a reducing agent
to form the compound of formula (I)
##STR00027##
[0085] In some embodiments, R.sup.0 can be selected from the group
consisting of H, OH, protected hydroxyl, alkyl, alkenyl, alkynyl,
acyl, aryl, heteroaryl, cycloalkyl or heterocycle;
[0086] wherein the alkyl, alkenyl, alkynyl or acyl is optionally
substituted with one or more substituents independently selected
from the group consisting of halogen, --OH, alkyl, --O-alkyl,
NR.sup.IR.sup.J, --S-alkyl, --SO-alkyl, --SO.sub.2-alkyl, alkenyl,
alkynyl, aryl, heteroaryl, cycloalkyl or heterocycle; wherein
R.sup.I and R.sup.J are each independently selected from hydrogen
and C.sub.1-4 alkyl;
[0087] wherein the aryl or heteroaryl, whether alone or as part of
a substituent group, is optionally substituted with one or more
substituents independently selected from the group consisting of
halogen, --OH, alkyl, --O-alkyl, --COOH, --C(O)--C.sub.1-4 alkyl,
--C(O)O--C.sub.1-4 alkyl, NR.sup.LR.sup.M, --S-alkyl, --SO-alkyl
and --SO.sub.2-alkyl; wherein R.sup.L and R.sup.M are each
independently selected from hydrogen and C.sub.1-4 alkyl.
[0088] In other embodiments, R.sup.0 and R.sup.1 are each
independently selected from the group consisting of hydrogen and
alkyl; wherein the alkyl is optionally substituted with one or more
substituents independently selected from the group consisting of
alkyl, alkenyl, alkynyl and aryl.
[0089] In some embodiments, R.sup.2 is selected from the group
consisting of H, OH, protected hydroxyl, alkyl, alkenyl, alkynyl,
acyl, aryl, heteroaryl, cycloalkyl or heterocycle;
[0090] wherein the alkyl, alkenyl, alkynyl or acyl is optionally
substituted with one or more substituents independently selected
from the group consisting of halogen, --OH, alkyl, --O-alkyl,
NR.sup.AR.sup.B, --S-alkyl, --SO-alkyl, --SO.sub.2-alkyl, alkenyl,
alkynyl, aryl, heteroaryl, cycloalkyl or heterocycle; wherein
R.sup.A and R.sup.B are each independently selected from hydrogen
and C.sub.1-4 alkyl;
[0091] wherein the aryl or heteroaryl, whether alone or as part of
a substituent group, is optionally substituted with one or more
substituents independently selected from the group consisting of
halogen, --OH, alkyl, --O-alkyl, --COOH, --C(O)--C.sub.1-4 alkyl,
--C(O)O--C.sub.1-4 alkyl, NR.sup.CR.sup.D, --S-alkyl, --SO-alkyl
and --SO.sub.2-alkyl; wherein R.sup.C and R.sup.D are each
independently selected from hydrogen and C.sub.1-4 alkyl.
[0092] In one embodiment, the R groups, e.g., R.sup.A and R.sup.B,
R.sup.C and R.sup.D, etc., and the nitrogen atom to which they are
bound can optionally form a 4 to 6 membered, saturated, partially
unsaturated or aromatic ring structure; wherein the 4 to 6
membered, saturated, partially unsaturated or aromatic ring
structure is optionally substituted with one, two or more
substituents independently selected from the group consisting of
--COOH, C(O)--C.sub.1-4 alkyl and --C(O)O--C.sub.1-4 alkyl.
[0093] FIG. 1 shows exemplary synthetic pathways of the present
disclosure. The substituents, e.g., R groups, are defined herein.
As shown in FIG. 1, the R.sub.4 group can be selected from the
group consisting of a substituted or unsubstituted alkyl,
substituted or unsubstituted alkenyl, substituted or unsubstituted
alkynyl, substituted or unsubstituted acyl, substituted or
unsubstituted aryl, substituted or unsubstituted cycloalkyl,
substituted or unsubstituted cycloalkenyl, substituted or
unsubstituted heterocycle or substituted or unsubstituted
heteroaryl.
[0094] As used herein the term "alkyl", whether alone or as part of
a substituent group, refers to a saturated C.sub.1-C.sub.n carbon
chain, wherein the carbon chain may be straight or branched;
wherein n can be 2, 3, 4, 5, 6, 7, 8, 9 or 10. Suitable examples
include, but are not limited to methyl, ethyl, propyl, isopropyl,
butyl, isobutyl, sec-butyl, t-butyl, n-pentyl and n-hexyl.
[0095] As used herein the term "alkenyl", whether alone or as part
of a substituent group, refers to a C.sub.2-C.sub.n carbon chain,
wherein the carbon chain may be straight or branched, wherein the
carbon chain contains at least one carbon-carbon double bond, and
wherein n can be 3, 4, 5, 6, 7, 8, 9 or 10.
[0096] As used herein the term "alkynyl", whether alone or as part
of a substitutent group, refers to a C.sub.2-C.sub.n, wherein the
carbon chain may be straight or branched, wherein the carbon chain
contains at least one carbon-carbon triple bond, and wherein n can
be 3, 4, 5, 6, 7, 8, 9 or 10.
[0097] As used herein the term "aryl", whether alone or as part of
a substituent group, refers to an unsubstituted carbocylic aromatic
ring comprising between 6 to 14 carbon atoms. Suitable examples
include, but are not limited to, phenyl and naphthyl.
[0098] As used herein the term "protected hydroxyl" refers to a
hydroxyl group substituted with a suitably selected oxygen
protecting group. More particularly, a "protected hydroxyl" refers
to a substituent group of the formula --OPG.sup.1 wherein PG.sup.1
is a suitably selected oxygen protecting group. During any of the
processes for preparation of the compounds of the present
disclosure it may be necessary and/or desirable to protect
sensitive or reactive groups on any of the molecules concerned.
This may be achieved by means of conventional protecting groups,
such as those described in Protective Groups in Organic Chemistry,
ed. J. F. W. McOmie, Plenum Press, 1973; and T. W. Greene & P.
G. M. Wuts, Protective Groups in Organic Synthesis, John Wiley
& Sons, 1991. The protecting groups may be removed at a
convenient subsequent stage using methods known from the art.
[0099] As used herein the term "oxygen protecting group" refers to
a group which may be attached to an oxygen atom to protect said
oxygen atom from participating in a reaction and which may be
readily removed following the reaction. Suitable oxygen protecting
groups include, but are not limited to, acetyl, benzoyl,
t-butyl-dimethylsilyl, trimethylsilyl (TMS), MOM and THP. Other
suitable oxygen protecting groups may be found in texts such as T.
W. Greene & P. G. M. Wuts, Protective Groups in Organic
Synthesis, John Wiley & Sons, 1991.
[0100] As used herein the term "nitrogen protecting group" refers
to a group which may be attached to a nitrogen atom to protect said
nitrogen atom from participating in a reaction and which may be
readily removed following the reaction. Suitable nitrogen
protecting groups include, but are not limited to,
carbamates--groups of the formula --C(O)O--R wherein R can be
methyl, ethyl, t-butyl, benzyl, phenylethyl,
CH.sub.2.dbd.CH--CH.sub.2--, and the like; amides--groups of the
formula --C(O)--R' wherein R' can be methyl, phenyl,
trifluoromethyl, and the like; N-sulfonyl derivatives--groups of
the formula --SO.sub.2--R'' wherein R'' can be tolyl, phenyl,
trifluoromethyl, 2,2,5,7,8-pentamethylchroman-6-yl-,
2,3,6-trimethyl-4-methoxybenzene, and the like. Other suitable
nitrogen protecting groups may be found in texts such as T. W.
Greene & P. G. M. Wuts, Protective Groups in Organic Synthesis,
John Wiley & Sons, 1991.
[0101] As used herein the term "acyl" refers to a group of the
formula --CO--C.sub.n wherein C.sub.n represent a straight or
branched alkyl chain wherein n can be 1, 2, 3, 4, 5, 6, 7, 8, 9 or
10.
[0102] As used herein the term "heteroaryl" refers to any five or
six membered monocyclic aromatic ring structure containing at least
one heteroatom selected from the group consisting of O, N and S,
and optionally containing one to three additional heteroatoms
independently selected from the group consisting of O, N and S; or
a nine or ten membered bicyclic aromatic ring structure containing
at least one heteroatom selected from the group consisting of O, N
and S, and optionally containing one to four additional heteroatoms
independently selected from the group consisting of O, N and S. The
heteroaryl group may be attached at any heteroatom or carbon atom
of the ring such that the result is a stable structure. Examples of
suitable heteroaryl groups include, but are not limited to,
pyrrolyl, furyl, thienyl, oxazolyl, imidazolyl, purazolyl,
isoxazolyl, isothiazolyl, triazolyl, thiadiazolyl, pyridyl,
pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, furazanyl,
indolizinyl, indolyl, isoindolinyl, indazolyl, benzofuryl,
benzothienyl, benzimidazolyl, benzthiazolyl, purinyl, quinolizinyl,
quinolinyl, isoquinolinyl, isothiazolyl, cinnolinyl, phthalazinyl,
quinazolinyl, quinoxalinyl, naphthyridinyl and pteridinyl.
[0103] As used herein the term "cycloalkyl" refers to any
monocyclic ring containing from four to six carbon atoms, or a
bicyclic ring containing from eight to ten carbon atoms. The
cycloalkyl group may be attached at any carbon atom of the ring
such that the result is a stable structure. Examples of suitable
cycloalkyl groups include, but are not limited to, cyclopropyl,
cyclobutyl, cyclopentyl and cyclohexyl.
[0104] As used herein the term "heterocycle" refers to any four to
six membered monocyclic ring structure containing at least one
heteroatom selected from the group consisting of O, N and S, and
optionally containing one to three additional heteroatoms
independently selected from the group consisting of O, N and S; or
an eight to ten membered bicyclic ring structure containing at
least one heteroatom selected from the group consisting of O, N and
S, and optionally containing one to four additional heteroatoms
independently selected from the group consisting of O, N and S. The
heterocycle group may be attached at any heteroatom or carbon atom
of the ring such that the result is a stable structure. Examples of
suitable heterocycle groups include, but are not limited to,
azetidine, azete, oxetane, oxete, thietane, thiete, diazetidine,
diazete, dioxetane, dioxete, dithietane, dithiete, pyrrolidine,
pyrrole, tetrahydrofuran, furan, thiolane, thiophene, piperidine,
oxane, thiane, pyridine, pyran and thiopyran.
[0105] The groups of the present disclosure can be unsubstituted or
substituted, as herein defined. In addition, the substituted groups
can be substituted with one or more groups such as a
C.sub.1-C.sub.6 alkyl, C.sub.1-4 alkyl, --O--C.sub.1-4 alkyl,
hydroxyl, amino, (C.sub.1-4 alkyl)amino, di(C.sub.1-4 alkyl)amino,
--S--(C.sub.1-4 alkyl), --SO--(C.sub.1-4 alkyl),
--SO.sub.2--(C.sub.1-4 alkyl), halogen, aryl, heteroaryl, and the
like.
[0106] With reference to substituents, the term "independently"
means that when more than one of such substituents is possible,
such substituents may be the same or different from each other.
[0107] The compounds of the present disclosure can contain at least
one hydroxyl group. These at least one hydroxyl group may form an
ester with inorganic or organic acid. In particular,
pharmaceutically acceptable acids. The ester(s) may form chiral
carbons. The present disclosure is directed toward all
stereo-chemical forms of the compounds of the present disclosure,
including those formed by the formation of one or more ester
groups.
[0108] In one embodiment, "a" can be 0, 1 or 2. In particular, "a"
can be 1 or 2. More particular, "a" can be 1.
[0109] In another embodiment, R.sup.1 can be C.sub.1-12 alkyl or
C.sub.1-12 alkenyl. In particular, R.sup.1 can be C.sub.1-4 alkyl.
More particular, R.sup.1 can be a methyl group.
[0110] In another embodiment, R.sup.2 is a C.sub.1-12 alkyl
optionally substituted with a cycloalkyl or heterocycle. The
substituted cycloalkyl or heterocycle can be optionally substituted
with a --COOH, --C(O)--C.sub.1-4 alkyl, or --C(O)O--C.sub.1-4 alkyl
group. In particular, R.sup.2 can be a methyl, ethyl, n-propyl,
n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, 2-methyloctan-2-yl
group or
##STR00028##
[0111] In one embodiment, R.sup.2 can be a n-propyl group. In
another embodiment, R.sup.2 can be n-pentyl group. In another
embodiment, R.sup.2 can be
##STR00029##
[0112] In another embodiment, R.sup.3 is hydrogen or a C.sub.1-4
alkyl. In particular, R.sup.3 can be a hydrogen or a methyl group.
More particular, R.sup.3 can be hydrogen.
[0113] In yet another embodiment, "a" can be 1, R.sup.1 can be a
methyl group, R.sup.2 can be a n-pentyl group and R.sup.3 can be
hydrogen.
[0114] Examples of compounds of formula (I) include ethyl
cannabidiolate, delta-9-tetrahydrocannabidiol and
delta-8-tetrahydrocannabidiol.
[0115] Examples of compounds of formula (II) include
4,6-dibromo-olivetol or 4,6-dibromo-divarinol.
[0116] Examples of compounds of formula (III) include menthadienol,
1-hydroxymethyl-4(1-methylethenyl)-cyclohex-2-ene-1-ol, and
cyclohex-2-enol. In one embodiment, the coupling of
dibromo-olivetol, and related compounds as provided in the present
disclosure, can be performed using a cyclic olefin containing a
double bond and a hydroxy-group at a conjugated position. Examples
of compounds of formula (III) can also include a cyclic olefin
containing a double bond and a hydroxy-group at a conjugated
position.
[0117] In one embodiment, a suitably substituted compound of
formula (II) being a known compound or compound prepared by known
methods, wherein each X is independently selected from the group
consisting of Br, F, I and Cl, particularly both X substituents are
the same and are selected from the group consisting of Br, F, I and
Cl, more particularly Br, F or Cl, or more particularly Br or F, or
even more particularly Br, can be reacted with a suitably
substituted compound of formula (III) being a known compound or
compound prepared by known methods, wherein R.sup.0 is H or a
suitably selected leaving group such as OH, Cl, Br, F, I, tosylate,
mesylate, acetate, and the like, in particular OH. The reaction can
occur in the presence of a suitably selected protic or Lewis acid
catalyst, for example p-toluene sulfonic acid,
trifluoromethanesulfonic acid, trifluoroacetic acid, acetic acid,
sulfuric acid, iron(II) chloride, scandium(III) triflate, zinc
chloride, aluminum chloride, and the like. The reaction can occur
neat or in a suitably selected solvent or mixture of solvents, for
example methylene chloride, chloroform, 1,2-dichloroethane,
cyclohexane, toluene, acetonitrile, tert-butyl methyl ether, or
combinations thereof, and the like. The reaction can form a
compound of formula (IV).
[0118] The compound of formula (IV) can be cyclized by reacting
with a second suitably selected Lewis acid catalyst, for example
BF.sub.3 diethyl etherate, BF.sub.3*AcOH, tri-isobutyl aluminum,
and the like. The cyclization can also be performed using protic
acids, such as p-toluene sulfonic acid. The cyclization reaction
can occur in a suitably selected solvent or mixture of solvents,
for example, methylene chloride, chlorobenzene, acetone,
1,2-dichloroethanen-heptane, acetonitrile, toluene, and the like.
The cyclization reaction can form a compound of formula (V).
[0119] The compound of formula (V) can be reacted to remove the X
substituent groups, more particularly, the compound of formula (V)
can be reacted with a suitably selected reducing agent, for
example, sodium sulfite, potassium sulfite, palladium/carbon in
combination with hydrogen, and the like; in the presence of a
suitably selected base, such as sodium hydroxide, triethylamine,
sodium carbonate, tripotassium phosphate, potassium tert-butoxide,
and the like. The reduction reaction can occur in a suitably
selected polar solvent or mixture of polar solvents, or mixture of
apolar and polar solvents, for example, methanol or a mixture of
methanol and water, acetonitrile, ethanol, acetone, isopropanol,
n-butanol, dichloromethane, tetrahydrofuran, tert-butyl methyl
ether or a mixture of organic solvent and water, and the like. The
polar solvent or mixture of polar solvents can also be selected
from the group consisting of acetonitrile, methylene chloride, or
combinations thereof, and the like. The reduction reaction can form
the compound of formula (I).
[0120] The dihalo-compound, e.g., formula (II), can be contained in
non-aqueous solvents or a mixture of solvents such as
dichloromethane, toluene, tert-butyl methyl, n-heptane, and the
like. The non-aqueous solvent can also contain a desiccating agent.
The desiccating agent can be added to remove adventitious moisture
from the reaction mixture. The amount of desiccating agent in the
dihalo-compound solution can be up to about 1, 2, 3, 4, 5, 6, 7, 8,
9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,
26, 27, 28, 29 or 30% (g of desiccating agent/mL of solvent). These
values can be used to define a range, such as about 1 and about
10%, or about 10 and about 20%.
[0121] In one embodiment, the amount of desiccating agent can be
about 5% to about 20% g/mL of anhydrous MgSO.sub.4 per mL DCM. For
example, a lower amount can be used, e.g., 5% g/mL, if the reagents
are anhydrous, e.g., MgSO.sub.4, dibromo-Olivetol, pTSA. A higher
amount can be used, e.g., 20% g/mL, if the reagents are
mono-hydrates, e.g., dibromo-Olivetol and pTSA mono-hydrates. In
one embodiment, the amount can be about 14.5% g/mL. In some
embodiments, the amount of desiccating agent can be 0% if the
compound, e.g., menthadienol, is present in excess amounts, such as
greater than about 3 eq.
[0122] The amount of desiccating agent per starting material can
also be expressed as a molar ratio of desiccating agent to starting
material. The amount can be about 1:1, 1.5:1, 2:1, 2.5:1, 3:1,
3.5:1, 4:1, 4.5:1 or about 5:1. These values can be used to define
a range, such as about 1.5:1 to about 3.5:1. In one embodiment, the
ratio is about 2.8:1.
[0123] The desiccating agent can be any agent or compound that does
not interfere with the reaction and can remove moisture from the
reaction mixture. The desiccating agent can be selected from the
group consisting of an anhydrous inorganic salt, molecular sieve,
activated charcoal, silica gel, or combinations thereof. In one
embodiment, the desiccating agent is anhydrous magnesium
sulfate.
[0124] The reaction between compounds of formula (III) and formula
(II) can be carried out with the relative amounts of compounds of
formula (III) and formula (II) of about 0.3, 0.4, 0.5, 0.6, 0.7,
0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1,
2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5,
3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9,
5, 5.1, 5.2, 5.3, 5.4 or 5.5 equivalents of formula (III) to
formula (II). These values can be used to define a range, such as
about 0.5 and about 5 equivalents, or about 0.5 and about 3.5
equivalents or about 1.1 to about 1.7 equivalents.
[0125] The compound of formula (III) can be added to the compound
of formula (II), or a solution containing formula (II), slowly. The
compound of formula (III) can be added to the compound of formula
(II), or a solution containing formula (II), over 0.1, 0.2, 0.3,
0.4, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 9, 10,
11, 12, 16, 20 or about 24 hours. These values can be used to
define a range, such about 2 to about 12 hours, or about 4 to about
8 hours. The compound can be added in increments or portions over
the time period. For example, the compound can be added over 7
hours as follows: t=0: 0.65 eq; t=1 h: +0.65 eq; t=4 h: +0.3 eq and
optionally t=7 h: +0.1 eq.
[0126] After addition, the reaction mixture can be stirred for an
additional time. The reaction mixture can be stirred for an
additional 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, 12, 16, 20, 24, 36 or 48 hours. These values can
be used to define a range, such as about 1 to about 3 hours, or
about 6 to about 48 hours, or about 12 to about 24 hours, or about
14 to about 18 hours.
[0127] One skilled in the art will recognize that the reaction or
process step(s) as herein described can proceed for a sufficient
period of time until the reaction is complete, as determined by any
method known to one skilled in the art, for example, chromatography
(e.g., HPLC). In this context a "completed reaction or process
step" shall mean that the reaction mixture contains a significantly
diminished amount of the starting
material(s)/reagent(s)/intermediate(s) and a significantly reduced
amount of the desired product(s), as compared to the amounts of
each present at the beginning of the reaction.
[0128] During the addition, during the additional stir time or
both, the reaction mixture can be held at a specific temperature or
held within a range of temperatures. The reaction mixture can be
held at -80.degree. C., -70.degree. C., -60.degree. C., -50.degree.
C., -40.degree. C., -30.degree. C., -20.degree. C., -10.degree. C.,
0.degree. C., 10.degree. C., 20.degree. C., 30.degree. C.,
40.degree. C., 50.degree. C., 60.degree. C., 70.degree. C.,
80.degree. C., 90.degree. C., 100.degree. C., 110.degree. C. or
about 120.degree. C. These values can be used to define a range,
such as about -40.degree. C. to about 40.degree. C., or about
-35.degree. C. to about -25.degree. C., or about -0.degree. C. to
about 50.degree. C.
[0129] The reaction between compounds of formula (III) and formula
(II) can be carried out in the presence of a protic or Lewis acid
catalyst. The protic acid can be an alkyl sulfonic acid or an aryl
sulfonic acid wherein the alkyl group can be a C.sub.1-C.sub.10
alkyl, and the aryl group can be a phenyl. The protic acid can be
an alkyl-phenyl sulfuric acid or fluoro-sulfonic acid or hydrohalic
acid where the halogen is F, Cl, Br or I. In one embodiment, the
protic acid is p-toluenesulfonic acid, acetic acid, sulfuric acid,
trifluoroacetic acid, scandium triflate, oxalic acid, benzoic acid,
phosphoric acid, formic acid or combinations thereof.
[0130] The Lewis acid catalyst can be of the general formula MY
wherein M can be boron, aluminum, scandium, titanium, yttrium,
zirconium, lanthanum, lithium, hafnium, or zinc and Y can be F, Cl,
Br, I, trifluoroacetate (triflate), alkoxide or combinations
thereof. The Lewis acid catalyst can be selected from the group
consisting of zinc triflate, ytterbium triflate, yttrium triflate,
scandium triflate and combinations thereof. In one embodiment, the
Lewis acid catalyst is a triflate, such as zinc triflate or
scandium triflate.
[0131] The amount of the protic or Lewis acid catalyst, e.g.,
p-toluenesulfonic acid, in the reaction between compounds of
formula (III) and formula (II) can be about 0.5 mol %, 1 mol %, 2
mol %, 3 mol %, 4 mol %, 5 mol %, 6 mol %, 7 mol %, 8 mol %, 9 mol
%, 10 mol %, 20 mol %, 30 mol %, 40 mol %, 50 mol %, 60 mol %, 70
mol %, 80 mol %, 90 mol %, 100 mol %, or about 120 mol % with
respect to the compound of formula (II). These values can be used
to define a range, such as about 4 mol % to about 6 mol %, 20 mol %
to about 80 mol %, or about 40 mol % to about 60 mol %.
[0132] The reaction between compounds of formula (III) and formula
(II) can be carried out in an organic solvent. The organic solvent
can be aprotic. The organic solvent can be selected from the group
consisting of methylene chloride, chloroform, trichloroethylene,
methylene bromide, bromoform, hexane, heptane, toluene, xylene, and
combinations thereof.
[0133] The compound of formula (IV) can be cyclized to form a
compound of formula (V) in the presence of a Lewis acid catalyst,
protic acid, or combinations thereof.
[0134] The Lewis acid catalyst can be of the general formula MY
wherein M can be boron, aluminum, scandium, titanium, yttrium,
zirconium, lanthanum, lithium, hafnium or zinc, and Y can be can be
F, Cl, Br, I, trifluoroacetate (triflate), alkoxide or combinations
thereof. The Lewis acid catalyst can be selected from the group
consisting of zinc triflate, ytterbium triflate, yttrium triflate,
scandium triflate and combinations thereof. In one embodiment, the
Lewis acid catalyst is a triflate, such as zinc triflate or
scandium triflate.
[0135] The amount of Lewis acid catalyst in the cyclization
reaction can be about 0.5 mol %, 1 mol %, 2 mol %, 5 mol %, 10 mol
%, 20 mol %, 30 mol %, 40 mol %, 50 mol %, 60 mol %, 70 mol %, 80
mol %, 90 mol %, 100 mol %, or about 120 mol % with respect to the
compound of formula (IV). These values can be used to define a
range, such as about 0.5 mol % to about 10 mol %.
[0136] The cyclization reaction can be carried out in carried out
in a suitably selected organic solvent or mixture of organic
solvents. The organic solvent can be selected from the group
consisting of a hydrocarbon, aromatic hydrocarbon, halogenated
hydrocarbon, ether, ester, amide, nitrile, carbonate, alcohol,
carbon dioxide, and mixtures thereof. In one embodiment, the
organic solvent is dichloromethane.
[0137] The temperature of the cyclization reaction can be held at a
specific temperature or held within a range of temperatures. The
reaction mixture can be held at -40.degree. C., -30.degree. C.,
-20.degree. C., -10.degree. C., 0.degree. C., 10.degree. C.,
20.degree. C., 30.degree. C., 40.degree. C., 50.degree. C.,
60.degree. C., 70.degree. C., 80.degree. C., 90.degree. C.,
100.degree. C., 110.degree. C. or about 120.degree. C. These values
can be used to define a range, such as about -20.degree. C. to
about 50.degree. C., or about 0.degree. C. to about 30.degree.
C.
[0138] The compound of formula (V) can be reacted with a reducing
agent to form the compound of formula (I). The compound of formula
(V) can be dissolved in a polar solvent and can be treated with a
reducing agent in the presence of a base to produce the compound of
formula (I).
[0139] The polar solvent can be water, alcohol, or combinations
thereof, e.g., a water-alcohol mixture. The alcohol can be selected
from the list consisting of methanol, ethanol, 1-propanol,
2-propanol, 1-butanol, 2-butanol, 2-methyl-1-propanol and
2-methyl-2-propanol. In one embodiment, the solvent is
methanol.
[0140] As used herein, the term "reducing agent" refers to an agent
having the ability to add one or more electrons to an atom, ion or
molecule. The reducing agent can be a sulfur-containing compound,
or Pd/C in the presence of hydrogen. The sulfur containing compound
can be a sulfur-containing reducing agent having the ability to
reduce C--X bonds of a compound of formula (IV) to C--H bonds.
[0141] The sulfur-containing compound can be a sulfur-containing
inorganic acid or salt thereof, including, for example,
hydrosulfuric acid (H.sub.2S), sulfurous acid (H.sub.2SO.sub.3),
thiosulfurous acid (H.sub.2SO.sub.2O.sub.2), dithionous acid
(H.sub.2S.sub.2O.sub.4), disulfurous acid (H.sub.2S.sub.2O.sub.5),
dithionic acid (H.sub.2S.sub.2O.sub.2), trithionic acid
(H.sub.2S.sub.3O.sub.6) and salts thereof. The sulfur-containing
inorganic salt can be an alkali metal salt or an alkaline earth
metal salt. For example, the salt can be a monovalent or divalent
cation selected from Li.sup.+, Na.sup.+, K.sup.+, Rb.sup.+,
Cs.sup.+, Fr.sup.+, Be.sup.2+, Mg.sup.2+, Ca.sup.2+, Sr.sup.2+,
Ba.sup.2+, or Ra.sup.2+. In one embodiment, the salt can be
selected from the group consisting of Li.sup.+, Na.sup.+, K.sup.+,
Mg.sup.2+, Ca.sup.2+ and combinations thereof.
[0142] The sulfur-containing inorganic salt can also be an ammonium
salt (NH.sub.4.sup.+) or a quaternary ammonium salt. For example,
the sulfur-containing inorganic acid salt can be a tetra-alkylated
ammonium salt, e.g., a quaternary ammonium salt substituted with
four alkyl groups. The alkyl groups can be a C.sub.1-C.sub.18. The
tetraalkylated ammonium salts can be a tetramethylammonium salt, a
tetraethylammonium salt, a tetrapropylammonium salt, a
tetrabutylammonium salt, or combinations thereof.
[0143] The sulfur-containing inorganic acid or salt thereof can
also be one which dissociates into a bisulfite ion
(HSO.sub.3.sup.-) and/or a sulfite ion (SO.sub.3.sup.2-) in the
reaction mixture. Sulfurous acid (H.sub.2SO.sub.3) can generally
exist as a solution of SO.sub.2 (commonly about 6%) in water. The
pKa of sulfurous acid (H.sub.2SO.sub.3) is about 1.78 and its
ionization expression is:
H.sub.2O+SO.sub.2.rarw..fwdarw.H.sub.2SO.sub.3.rarw..fwdarw.H.sup.++HSO.s-
ub.3.sup.-.rarw..fwdarw.H.sup.++SO.sub.3.sup.2-. In one embodiment,
the sulfur-containing compound is sodium sulfite.
[0144] The molar ratio amount of sulfur-containing compound to the
compound of formula (IV) in the reduction reaction mixture can be
about 0.8:1, 1:1, 1.5:1, 2:1, 3:1, 4:1, 5:1 or greater. These
values can define a range, such as about 2:1 to about 4:1, or about
2.5:1 to about 3.5:1. In one embodiment, the ratio is about
3:1.
[0145] The base can be an organic or weak inorganic base. In one
embodiment, the base can be an organic base, e.g., a tertiary
amine. The base can be selected from the group consisting of
trimethylamine, triethylamine, tripropylamine,
diisopropylmethylamine, N-methylmorpholine, triethanolamine and
combinations thereof. In one embodiment, the base is triethylamine.
In another embodiment, the base can be a weak inorganic base, e.g.,
a carbonate or bicarbonate salt. The base can be a carbonate or
bicarbonate salt selected from the group consisting of Li.sup.+,
Na.sup.+, K.sup.+, Mg.sup.2+, Ca.sup.2+ and combinations
thereof.
[0146] The molar ratio amount of base to the compound of formula
(IV) in the reduction reaction mixture can be about 0:1, 1:1,
1.5:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1 or greater. These values
can define a range, such as about 3.5:1 to about 4.5:1, or about
4:1 to about 6:1. In one embodiment, the ratio is about 4:1.
[0147] The reduction reaction can be carried out at a reflux
temperature, including a temperature elevated by high pressure, of
the solvent or solvent mixture for a duration of about 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, 12, 16, 20, 24, 28, 30, 32, 36 or about 48
hours; or any amount of time required to reach a desired endpoint
(wherein the desired endpoint can be determined by for example, a
percent conversion of starting material or an intermediate
material). In some embodiments, the conversion of the di-halogen to
the mono-halogen proceeds faster than the conversion of the
mono-halogen to the fully dehalogenated product. These values can
define a range, such as about 10 to about 30 hours. In one
embodiment, the reduction reaction can be carried out at reflux in
a methanol-water mixture for a duration of about 16 hours to about
24 hours, or about 20 to about 28 hours.
[0148] The reflux temperature can be at 20.degree. C., Room
Temperature, 30.degree. C., 40.degree. C., 50.degree. C.,
60.degree. C., 65.degree. C., 70.degree. C., 75.degree. C.,
80.degree. C., 85.degree. C., 90.degree. C., 95.degree. C.,
100.degree. C., 110.degree. C. or about 120.degree. C. These values
can be used to define a range, such as about 20.degree. C. to about
100.degree. C., or about RT to about 50.degree. C., or about
60.degree. C. to about 85.degree. C., or about 72.degree. C. to
about 76.degree. C. In some embodiments, subsequent distillation
can be performed. The distillation can be performed at the same
temperatures listed above, e.g., 85.degree. C.
[0149] The reflux pressure can be at atmospheric pressure. In some
embodiments, the reflex can be done at a pressure of about 100,
200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500,
3000, 3500, or about 4000 mbar. These values can be used to define
a range, such as about 900 to about 3000 mbar.
[0150] The reaction products, e.g., the reduction reaction
products, of the present disclosure can further be purified by
chromatography, countercurrent extraction, distillation, or
combinations thereof. The reaction products of the present
disclosure can also be purified by crystallization.
[0151] In another embodiment, the present disclosure relates to a
process for the preparation of a compound of formula (I) including
reacting a compound of formula (II) with a compound of formula
(III) in the presence of a protic or first Lewis acid catalyst to
form a compound of formula (IV), as described above. The compound
of formula (IV) can then be reacted with a reducing agent to form a
compound of formula (VI).
##STR00030##
[0152] The compound of formula (IV) can be dissolved in a polar
solvent and can be treated with a reducing agent in the presence of
a base to produce the compound of formula (VI). The reduction
reaction, conditions, components, parameters, etc. are similar to
the reaction of a compound of formula (V) reacting with a reducing
agent to form the compound of formula (I), as described above.
[0153] The compound of formula (VI) can then be reacted with a
second Lewis acid catalyst to form the compound of formula (I).
##STR00031##
[0154] The cyclization reaction, conditions, components,
parameters, etc. are similar to the cyclization reaction of a
compound of formula (IV) in the presence of a Lewis acid catalyst
to form a compound of formula (V), as described above.
[0155] In one embodiment, a suitably substituted compound of
formula (II) being a known compound or compound prepared by known
methods, wherein each X is independently selected from the group
consisting of Br, F, I and Cl, particularly both X substituent
groups are the same and are selected from the group consisting of
Br, F, I and Cl, more particularly Br F or Cl, or more particularly
Br or F, or even more particularly Br, is reacted with a suitably
substituted compound of formula (III), being a known compound or
compound prepared by known methods, wherein R.sup.0 is H or a
suitably selected leaving group such as OH, Cl, Br, F, I, tosylate,
mesylate, acetate, and the like, particularly OH, in the presence
of a suitably selected protic or Lewis acid catalyst, for example
p-toluene sulfonic acid. The reaction can occur in a suitably
selected solvent or mixture of solvents, for example methylene
chloride. The reaction can form a compound of formula (IV).
[0156] The compound of formula (IV) can be reacted to remove the X
substituent groups, more particularly, the compound of formula (IV)
can be reacted with a suitably selected reducing agent, for example
sodium sulfite. The reaction can occur in a suitably selected polar
solvent or mixture of polar solvents, for example methanol or a
mixture of methanol and water. The reaction can form a compound of
formula (VI).
[0157] The compound of formula (VI) can be cyclized by reacting
with a suitably selected second Lewis acid catalyst, for example
BF.sub.3, in a suitably selected solvent or mixture of solvents,
for example methylene chloride. The cyclization reaction can form a
compound of formula (I).
[0158] In different embodiments, the processes of the present
disclosure can be used to form compounds of the various formulas
provided that either the first, second or both Lewis acid
catalyst(s) is not an organo-aluminum Lewis acid catalyst.
[0159] In another embodiment, the present disclosure relates to a
process for the preparation of a compound of formula (VI)
##STR00032##
[0160] wherein a, R.sup.1, R.sup.2, R.sup.3 and are defined above,
unless otherwise specified below, or a pharmaceutically acceptable
salt or ester thereof. The process includes reacting a compound of
formula (II), wherein each X is independently selected from the
group consisting of Br, F, I and Cl, with a compound of formula
(III) wherein R.sup.0 is H or OH (or as otherwise defined herein)
in the presence of a protic or first Lewis acid catalyst to form a
compound of formula (IV), as described above. The compound of
formula (IV) can then be reacted with a reducing agent to form a
compound of formula (VI).
##STR00033##
[0161] The compound of formula (IV) can be dissolved in a polar
solvent and can be treated with a reducing agent in the presence of
a base to produce the compound of formula (VI). The reduction
reaction, conditions, components, parameters, etc. are similar to
the reaction of a compound of formula (V) reacting with a reducing
agent to form the compound of formula (I), as described above.
[0162] In one embodiment, "a" can be 0, 1 or 2. In particular, "a"
can be 1 or 2. More particular, "a" can be 1.
[0163] In another embodiment, R.sup.1 can be C.sub.1-12 alkyl or
C.sub.1-12 alkenyl. In particular, R.sup.1 can be C.sub.1-4 alkyl.
More particular, R.sup.1 can be a methyl group.
[0164] In another embodiment, R.sup.2 can be a C.sub.1-12 alkyl
optionally substituted with a cycloalkyl or heterocycle. The
substituted cycloalkyl or heterocycle can be optionally substituted
with a --COOH, --C(O)--C.sub.1-4 alkyl, or --C(O)O--C.sub.1-4 alkyl
group. In particular, R.sup.2 can be a methyl, ethyl, n-propyl,
n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, 2-methyloctan-2-yl
group or
##STR00034##
[0165] In one embodiment, R.sup.2 can be a n-propyl group. In
another embodiment, R.sup.2 can be n-pentyl group. In another
embodiment, R.sup.2 can be
##STR00035##
[0166] In another embodiment, R.sup.3 can be hydrogen or a
C.sub.1-4 alkyl. In particular, R.sup.3 can be a hydrogen or a
methyl group. More particular, R.sup.3 can be hydrogen.
[0167] In yet another embodiment, "a" can be 1, R.sup.1 can be a
methyl group, R.sup.2 can be a n-propyl or n-pentyl group and
R.sup.3 can be hydrogen.
[0168] Examples of compounds of formula (VI) include cannibidiol,
cannabidivarin and
##STR00036##
[0169] In another embodiment, the present disclosure relates to a
process for the preparation of a compound of formula (XI)
(delta-9-tetrahydrocannabidiol)
##STR00037##
[0170] or a pharmaceutically acceptable salt or ester thereof;
[0171] the process can include reacting a compound of formula
(XII), wherein each X is independently selected from Br, F, I or
Cl, with a compound of formula (XIII) (menthadienol) in the
presence of a protic or first Lewis acid catalyst to form a
compound of formula (XIV).
##STR00038##
[0172] The reaction, conditions, components, parameters, etc. of
the reaction of formula (XII) with a compound of formula (XIII) in
the presence of a protic or first Lewis acid catalyst to form a
compound of formula (XIV) are similar to the reaction of a compound
of formula (II) reacting with a compound of formula (III) to form
the compound of formula (IV), as described above.
[0173] The compound of formula (XIV) can then be cyclized by
reacting the compound of formula (XIV) with a second Lewis acid
catalyst to form a compound of formula (XV).
##STR00039##
[0174] The cyclization reaction, conditions, components,
parameters, etc. of the reaction of formula (XIV) with a second
Lewis acid catalyst to form a compound of formula (XV) are similar
to the cyclization reaction of a compound of formula (IV) in the
presence of a Lewis acid catalyst to form a compound of formula
(V), as described above.
[0175] The compound of formula (XV) can then be reacted with a
reducing agent to form the compound of formula (XI).
##STR00040##
[0176] The compound of formula (XV) can be dissolved in a polar
solvent and can be treated with a reducing agent in the presence of
a base to produce the compound of formula (XI). The reduction
reaction, conditions, components, parameters, etc. of formula (XV)
with a reducing agent to form a compound of formula (XI) are
similar to the reaction of a compound of formula (V) reacting with
a reducing agent to form the compound of formula (I), as described
above.
[0177] In one embodiment, a suitably substituted compound of
formula (XII), being a known compound or compound prepared by known
methods, wherein each X is independently selected from the group
consisting of Br, F, I and Cl; particularly both X substituent
groups are the same and are selected from the group consisting of
Br, F, I and Cl, more particularly Br, F or Cl, or more
particularly Br or F, or even more particularly Br, can be reacted
with a suitably substituted compound of formula (XIII), being a
known compound or compound prepared by known methods, wherein
R.sup.0 is H or a suitably selected leaving group such as OH, Cl,
Br, F, I, tosylate, mesylate, acetate, and the like, particularly
OH, in the presence of a suitably selected protic or Lewis acid
catalyst, for example p-toluene sulfonic acid. The reaction can
occur in a suitably selected solvent or mixture of solvents, for
example methylene chloride. The reaction can form a compound of
formula (XIV).
[0178] The compound of formula (XIV) can then be cyclized by
reacting with a suitably selected second Lewis acid catalyst, for
example BF.sub.3, in a suitably selected solvent or mixture of
solvent for example methylene chloride. The cyclization reaction
can form a compound of formula (XV).
[0179] The compound of formula (XV) can be reacted to remove the X
substituent groups, more particularly, the compound of formula (XV)
can be reacted with a suitably selected reducing agent, for example
sodium sulfite; in a suitably selected solvent or mixture of
solvents, for example methanol or a mixture of methanol and water.
The reaction can form the compound of formula (XI).
[0180] Certain of the disclosed compounds may exist in various
stereoisomeric forms. Stereoisomers are compounds that differ only
in their spatial arrangement. Enantiomers are pairs of
stereoisomers whose mirror images are not superimposable, most
commonly because they contain an asymmetrically substituted carbon
atom that acts as a chiral center. "Enantiomer" means one of a pair
of molecules that are mirror images of each other and are not
superimposable. Diastereomers are stereoisomers that contain two or
more asymmetrically substituted carbon atoms. "R" and "S" represent
the configuration of substituents around one or more chiral carbon
atoms.
[0181] "Racemate" or "racemic mixture" means a compound of
equimolar quantities of two enantiomers, wherein such mixtures
exhibit no optical activity, i.e., they do not rotate the plane of
polarized light.
[0182] The compounds of the present disclosure may be prepared as
individual enantiomers by either enantio-specific synthesis or
resolved from an enantiomerically enriched mixture. When the
stereochemistry of a disclosed compound is named or depicted, the
named or depicted stereoisomer can be at least 60%, 70%, 80%, 90%,
99% or 99.9% by weight pure relative to all of the other
stereoisomers. Percent by weight pure relative to all of the other
stereoisomers is the ratio of the weight of one stereoisiomer over
the weight of the other stereoisomers. When a single enantiomer is
named or depicted, the depicted or named enantiomer is at least
60%, 70%, 80%, 90%, 99% or 99.9% by weight optically pure. Percent
optical purity by weight is the ratio of the weight of the
enantiomer over the weight of the enantiomer plus the weight of its
optical isomer.
[0183] In another embodiment, the present disclosure can produce
the compounds of interest, e.g., compounds of formula (I), (VI),
(XI), (XVI), etc., in high stereospecificity, from the starting
materials, e.g., compounds of formula (II), etc. The
stereospecificity of the processes of the present disclosure can be
greater than about 60% ee, 75% ee, 80% ee, 85% ee, 90% ee, 95% ee,
97% ee, 98% ee, 99% ee. These values can define a range, such as
about 90% ee and about 99% ee.
[0184] Compounds that can be produced by the process of the present
disclosure can include (-)-trans-cannabidiol,
(-)-trans-.DELTA.-9-tetrahydrocannabinol, (-)-trans-cannabidiolic
acid, (-)-trans-.DELTA.-9-tetrahydrocannabinolic acid, intermediate
compounds thereof, derivative compounds thereof, as well as the
corresponding (+) enantiomer, and racemates.
[0185] The following table lists some of these compounds.
[0186] Structure Chemical name IUPAC
TABLE-US-00001 Structure Chemical name (IUPAC) (-)-CBD ##STR00041##
(1'R,2'R)-5'-methyl-4-pentyl-2'-(prop-1-
en-2-yl)-1',2',3',4'-tetrahydro-[1,1'- biphenyl]-2,6-diol (+)-CBD
##STR00042## (1'S,2'S)-5'-methyl-4-pentyl-2'-(prop-1-
en-2-yl)-1',2',3',4'-tetrahydro-[1,1'- biphenyl]-2,6-diol
(-)-.DELTA.6-CBD ##STR00043##
(1'R,2'R)-5'-methyl-4-pentyl-2'-(prop-1-
en-2-yl)-1',2',3',6'-tetrahydro-[1,1'- biphenyl]-2,6-diol
(+)-.DELTA.6-CBD ##STR00044##
(1'S,2'S)-5'-methyl-4-pentyl-2'-(prop-1-
en-2-yl)-1',2',3',6'-tetrahydro-[1,1'- biphenyl]-2,6-diol
(-)-.DELTA.9-THC ##STR00045## (6aR,10aR)-6,6,9-trimethyl-3-pentyl-
6a,7,8,10a-tetrahydro-6H- benzo[c]chromen-1-ol (+)-.DELTA.9-THC
##STR00046## (6aS,10aS)-6,6,9-trimethyl-3-pentyl-
6a,7,8,10a-tetrahydro-6H- benzo[c]chromen-1-ol (-)-.DELTA.8-THC
##STR00047## (6aR,10aR)-6,6,9-trimethyl-3-pentyl-
6a,7,10,10a-tetrahydro-6H- benzo[c]chromen-1-ol (+)-.DELTA.8-THC
##STR00048## (6aS,10aS)-6,6,9-trimethyl-3-pentyl-
6a,7,10,10a-tetrahydro-6H- benzo[c]chromen-1-ol (-)-(I)
##STR00049## (+)-(I) ##STR00050## (-)-(VI) ##STR00051## (+)-(VI)
##STR00052##
[0187] In another embodiment, the present disclosure relates to a
process for the preparation of a compound of formula (XI)
(delta-9-tetrahydrocannabidiol)
##STR00053##
[0188] or a pharmaceutically acceptable salt or ester thereof;
[0189] the process can include reacting a compound of formula
(XII), wherein each X is independently selected from Br, F, I or
Cl, with a compound of formula (XIII) (menthadienol) in the
presence of aprotic or first Lewis acid catalyst to for a compound
of formula (XIV).
##STR00054##
[0190] The reaction, conditions, components, parameters, etc. of
the reaction of formula (XII) with a compound of formula (XIII) in
the presence of a protic or first Lewis acid catalyst to form a
compound of formula (XIV) are similar to the reaction of a compound
of formula (II) reacting with a compound of formula (III) to form
the compound of formula (IV), as described above.
[0191] The compound of formula (XIV) can then be reacted with a
reducing agent to form the compound of formula (XVI).
##STR00055##
[0192] The compound of formula (XIV) can be dissolved in a polar
solvent and can be treated with a reducing agent in the presence of
a base to produce the compound of formula (XVI). The reduction
reaction, conditions, components, parameters, etc. of formula (XIV)
with a reducing agent to form a compound of formula (XVI) are
similar to the reaction of a compound of formula (V) reacting with
a reducing agent to form the compound of formula (I), as described
above.
[0193] The compound of formula (XVI) can then be cyclized by
reacting the compound of formula (XVI) with a second Lewis acid
catalyst to form a compound of formula (XI).
##STR00056##
[0194] The cyclization reaction, conditions, components,
parameters, etc. of the reaction of formula (XVI) with a second
Lewis acid catalyst to form a compound of formula (XI) are similar
to the cyclization reaction of a compound of formula (IV) in the
presence of a Lewis acid catalyst to form a compound of formula
(V), as described above.
[0195] In another embodiment, a suitably substituted compound of
formula (XII), being a known compound or compound prepared by known
methods, wherein each X is independently selected from the group
consisting of Br, F, I and Cl; particularly both X substituent
groups are the same and are selected from the group consisting of
Br, F, I and Cl, more particularly Br, F or Cl, or more
particularly Br or F, or even more particularly Br, is reacted with
a suitably substituted compound of formula (XIII), being a known
compound or compound prepared by known methods, wherein R.sup.0 is
H or a suitably selected leaving group such as OH, Cl, Br, F, I,
tosylate, mesylate, acetate, and the like, preferably OH, in the
presence of a suitably selected protic or Lewis acid catalyst, for
example p-toluene sulfonic acid. The reaction can occur in a
suitably selected solvent or mixture of solvents, for example
methylene chloride. The reaction can form a compound of formula
(XIV).
[0196] The compound of formula (XIV) can be reacted to remove the X
substituent groups, more particularly, the compound of formula
(XIV) can be reacted with a suitably selected reducing agent, for
example sodium sulfite. The reaction can occur in a suitably
selected solvent or mixture of solvents, for example methanol or a
mixture of methanol and water. The reaction can form a compound of
formula (XVI).
[0197] The compound of formula (XVI) can be cyclized by reacting
with a suitably selected second Lewis acid catalyst, for example
BF.sub.3, in a suitably selected solvent or mixture of solvent, for
example methylene chloride. The cyclization reaction can form the
compound of formula (XI).
[0198] In another embodiment, the present disclosure relates to a
process for the preparation of a compound of formula (XVI)
(cannabidiol)
##STR00057##
[0199] or a pharmaceutically acceptable salt or ester thereof;
[0200] the process can include reacting a compound of formula
(XII), wherein each X is independently selected from Br, F, I or
Cl, with a compound of formula (XIII) (menthadienol) in the
presence of a protic or first Lewis acid catalyst to form a
compound of formula (XIV).
##STR00058##
[0201] The reaction, conditions, components, parameters, etc. of
the reaction of formula (XII) with a compound of formula (XIII) in
the presence of a protic or first Lewis acid catalyst to form a
compound of formula (XIV) are similar to the reaction of a compound
of formula (II) reacting with a compound of formula (III) to form
the compound of formula (IV), as described above.
[0202] The compound of formula (XIV) can then be reacted with a
reducing agent to form the compound of formula (XVI).
##STR00059##
[0203] The compound of formula (XIV) can be dissolved in a polar
solvent and can be treated with a reducing agent in the presence of
a base to produce the compound of formula (XVI). The reduction
reaction, conditions, components, parameters, etc. are similar to
the reaction of a compound of formula (V) reacting with a reducing
agent to form the compound of formula (I), as described above.
[0204] In another embodiment, the present disclosure relates to a
process for the preparation of a compound of formula (XX)
##STR00060##
[0205] or a pharmaceutically acceptable salt or ester thereof, the
process can include reacting a compound of formula (XXI), wherein
each X is independently selected from Br, F, I or Cl, with a
compound of formula (XIII) in the presence of a protic or first
Lewis acid catalyst to form a compound of formula (XXII); and
##STR00061##
[0206] reacting the compound of formula (XXII) with a reducing
agent to form the compound of formula (XX)
##STR00062##
[0207] The compound of formula (XXII) can be dissolved in a polar
solvent and can be treated with a reducing agent in the presence of
a base to produce the compound of formula (XX). The reduction
reaction, conditions, components, parameters, etc. are similar to
the reaction of a compound of formula (V) reacting with a reducing
agent to form the compound of formula (I), as described above.
[0208] The present disclosure can produce the compounds of
interest, e.g., compounds of formula (I), (VI), (XI), (XVI), etc.,
in high yield, from the starting materials, e.g., compounds of
formula (II). The yield of the process of the present disclosure
can be greater than about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%,
68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%,
80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 9100, 92%,
93%, 94%, 95%, 96%, 97%, 98% or 99%. These values can define a
range, such as about 60% to about 85%, or about 90% to about
99%.
[0209] The disclosures of all cited references including
publications, patents, and patent applications are expressly
incorporated herein by reference in their entirety.
[0210] When an amount, concentration, or other value or parameter
is given as either a range, preferred range, or a list of upper
preferable values and lower preferable values, this is to be
understood as specifically disclosing all ranges formed from any
pair of any upper range limit or preferred value and any lower
range limit or preferred value, regardless of whether ranges are
separately disclosed. Where a range of numerical values is recited
herein, unless otherwise stated, the range is intended to include
the endpoints thereof, and all integers and fractions within the
range. It is not intended that the scope of the invention be
limited to the specific values recited when defining a range.
[0211] The present invention is further defined in the following
Examples. It should be understood that these Examples, while
indicating preferred embodiments of the invention, are given by way
of illustration only.
EXAMPLES
Example 1--Synthesis of Cannabidiol from 4,6-dibromo-Olivetol
[0212] Cannabidiol, or
(1'R,2'R)-5'-methyl-4''-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydro-
-[1,1''-biphenyl]-2'',6''-diol, was prepared according to the
present disclosure.
##STR00063##
[0213] Under a N.sub.2 atmosphere, 4,6-dibromo-olivetol (20.08 g,
59.40 mmol), magnesium sulfate (20.00 g, 164.5 mmol, 2.77 equiv.)
and para toluene sulfonic acid monohydrate (5.76 g, 29.8 mmol, 0.50
equiv.) were suspended in CH.sub.2Cl.sub.2 (187.4 g) and cooled to
between about -15 to -20.degree. C. To this white suspension a
clear solution of menthadienol (11.72 g, 76.99 mmol, 1.30 equiv.)
in CH.sub.2Cl.sub.2 (55.13 g) was added dropwise over 6 hours.
After stirring overnight at -15.degree. C., the suspension was
quenched with water (200.6 g). NaHCO.sub.3 (5.01 g, 59.6 mmol, 1.00
equiv.) was added in portions and the mixture was stirred for about
10 to 30 min at room temperature. The layers were separated and the
aqueous layer was re-extracted with CH.sub.2Cl.sub.2 (50.1 g). The
organic layer was concentrated to dryness (in vacuum).
[0214] The remaining viscous oil was dissolved in methanol (200 g).
This solution was combined with a solution of Na.sub.2SO.sub.3
(22.3 g, 177 mmol, 3 equiv.) in water (200 g). To the remaining
white suspension, N,N-diethylethanamine (29.9 g, 295 mmol, 5.00
equiv.) was added and the suspension was heated to reflux and
stirred for 20 hours. After re-cooling of the reaction mixture to
room temperature, conc. HCl (37 wt %) (16.2 g, 164 mmol, 2.78
equiv.) was added dropwise within 20 to 30 min to a pH value of 6.5
(at 20.degree. C.). N-heptane (80 g) was then added. The yellowish
emulsion was stirred for about 20 min at 30.degree. C. The layers
were separated. The aqueous layer was re-extracted with n-heptane
(50 g). The combined organic layers were dried over
Na.sub.2SO.sub.4, filtered and concentrated to have a ratio of
cannabidiol to n-heptane of 1:4. The solution was seeded and cooled
to -15.degree. C. over about 2 to 3 hours. The product was isolated
and washed with n-heptane.
[0215] The remaining white solid (m=16.0 g), was re-dissolved in
n-heptane (64 g) at 40.degree. C., cooled to 0.degree. C. and
stirred for 1 to 2 h at 0.degree. C. The product was isolated,
washed with n-heptane and dried in vacuum at 40-50.degree. C. The
obtained white crystalline powder (m=14.7 g, 79%) was analyzed by
UPLC with 99.96 area %.
Example 2--Variation of the Chain Length (C.sub.3H.sub.7 and
C.sub.5H.sub.11)
[0216] Synthesis of C3-olivetol analogue: The C3-analog of olivetol
was synthesized, starting from commercially available
3,5-dimethoxybenzoic acid as shown in FIG. 4. The synthesis of
3,5-dimethoxybenzoyl chloride [1] was first tested on a 1 g scale
by the treatment of 3,5-dimethoxybenzoic acid with 1.2 eq. of
SOCl.sub.2 in toluene at 100.degree. C. The reaction proceeded
smoothly and after 1 hour, a complete conversion was observed on
LC-MS. The solvents were evaporated and the product was stripped
twice with toluene to remove the excess SOCl.sub.2 to yield 1.15 g
of [1] (quantitative yield), which was used as such in further
experiments. Repetition of the reaction on 95 g scale was performed
and yielded a second batch of [1] (110 g, quantitative yield).
Synthesis of 3,5-dimethoxybenzoyl chloride [1]
##STR00064##
[0218] To a suspension of 3,5-dimethoxybenzoic acid (95 g, 521
mmol) in toluene (dry, 950 mL) was added thionyl chloride (74.4 g,
626 mmol, 45.4 ml) and a catalytic amount of DMF (0.2 mL). The
mixture was heated to 100.degree. C. and stirred for 6 hours. A
clear solution was formed. The mixture was allowed to cool to room
temperature and all volatiles evaporated in vacuo using a rotary
evaporator. The mixture was stripped twice with fresh toluene
(2.times.100 mL). Yield: 110 g of a brown oil (105% yield).
[0219] The preparation of N,3,5-trimethoxy-N-methylbenzamide [2]
was first investigated on a 1.10 g scale. To a stirred mixture of
[1] (1.10 g) and N,O-dimethyl-hydroxylamine HCl in DCM was added
triethylamine (3 eq.) at 0.degree. C. The mixture was allowed to
warm to room temperature and stirred over the weekend. Analysis
with LC-MS showed complete and clean formation of [2]. Aqueous
work-up yielded 0.95 g of a brown oil and subsequent analysis with
.sup.1H-NMR confirmed the structure. Repetition on 110 g scale was
performed and yielded a second batch of [2] (123 g, quantitative
yield).
Synthesis of N,3,5-trimethoxy-N-methylbenzamide [2]
##STR00065##
[0221] To a cold (0.degree. C.) mixture of 3,5-dimethoxybenzoyl
chloride (105 g, 523 mmol) and N,O-dimethylhydroxylamine
hydrochloride (61.3 g, 628 mmol) in dichloromethane (1000 mL) was
slowly added triethylamine (159 g, 1570 mmol, 218 mL). During the
addition, a thick suspension was formed (triethylamine HCl), which
hindered proper stirring. Extra DCM (200 mL) was added and the
mixture was stirred overnight. The reaction mixture was washed
twice with 50% diluted aqueous brine (2.times.500 mL) and dried the
organic phase on Na.sub.2SO.sub.4. Evaporated all volatiles in
vacuo using a rotary evaporator. Yield: 122.5 g of a brown oil
(104% yield).
[0222] With [2] available, the Grignard reaction towards
1-(3,5-dimethoxyphenyl)propan-1-one [3] was investigated on 0.5 g
scale. At 0.degree. C., a solution of the [2] in 2-Me-THF was added
drop-wise to a solution of ethyl magnesium bromide in 2-Me-THF in 5
minutes. After 3 hours, LC-MS showed the formation of two new main
products (at 1.74 and 2.11 min) as well as remaining starting
material (at 1.86 min). The peak at 2.11 minutes showed the correct
mass for [3] while the peak at 1.74 minutes showed a mass of 196 in
positive mode in the mass trace. The mixture was allowed to warm to
room temperature and stirred overnight. Subsequent analysis with
LC-MS showed no further conversion. Aqueous work-up yielded 1.15 g
of a brown oil which was purified by column chromatography.
[0223] All components were separated and both of the newly formed
products were characterized by LC-MS and .sup.1H-NMR. In this
manner, a batch of [3] (0.11 g of a colorless oil) was obtained and
the structure was confirmed. Of the unknown side product, 0.04 g
was isolated as a white solid. Both the observed mass in LC-MS and
the H-NMR spectrum indicated that this compound was an amide. The
.sup.1H-NMR spectrum and appearance are in agreement with the
literature (J. Am. Chem. Soc., 2014, 136, 6920-6928). The formation
of this side product can be explained by deprotonation of the
methoxy-group of the Weinreb amide by the basic Grignard reagent,
leading to demethoxylation.
[0224] With all reaction products known, repetition on a 0.36 g
scale was performed wherein solution of the [2] in 2-Me-TH was
added dropwise to a solution of ethyl magnesium bromide (1.1 eq.)
in 2-Me-TH at 0.degree. C. After stirring for 2 hours, LC-MS showed
a very similar pattern to the previous experiment with 47 area %
[3], 24 area % of the 3,5-dimethoxy-N-methylbenzamide and 27 area %
remaining starting material. A second aliquot of ethyl magnesium
bromide (1.1 eq.) was added and the mixture was allowed to warm to
room temperature overnight. Subsequent analysis with LC-MS showed a
complete consumption of [2] and the formation of a 1:1 mixture of
[3] and 3,5-dimethoxy-N-methylbenzamide. Unfortunately, the initial
selectivity towards [3] observed in the earlier sample was no
longer found.
[0225] The Grignard reaction towards [3] was continued without
further optimization and to remove the formed amide side product by
column chromatography. Thus, on 120 g scale, [2] was treated with
ethyl magnesium bromide at 0.degree. C. No problems were
encountered and [3] was formed as expected in a 59:36 ratio with
the 3,5-dimethoxy-N-methylbenzamide. Aqueous work-up yielded 97 g
of a brown oil which was purified by column chromatography using
silica and heptane:ethyl acetate (4:1) as eluent to yield 47 g of
[3] as a colourless oil in 45% yield. The oil crystallized upon
standing and analysis with LC-MS showed that the purity was
97%.
Synthesis of 1-(3,5-dimethoxyphenyl)propan-1-one [3]
##STR00066##
[0227] To a cold (0.degree. C.) solution of
N,3,5-trimethoxy-N-methylbenzamide (120 g, 533 mmol) in 2-Me-THF
(1000 mL) was slowly added ca. 3.2 M solution of ethylmagnesium
bromide in 2-Me-THF (608 mmol, 190 mL) in 4 hours. After stirring
for an additional 30 minutes, LC-MS showed partial conversion.
Slowly ca. 3.2 M solution of ethylmagnesium bromide (64.0 mmol, 20
mL) was added. The mixture was stirred for another 30 minutes, then
allowed to slowly warm to room temperature and stirred overnight.
The reaction mixture was poured into 1M aq. HCl (800 mL). The
layers were separated and the aqueous phase was extracted with
ethyl acetate (250 mL). The combined organic layers were washed
with brine (250 mL), then dried on Na.sub.2SO.sub.4. All volatiles
were evaporated in vacuo using a rotary evaporator. Un-purified
Product yield: 97 g of a brownish oil containing a white solid. The
isolated product was purified by gravity column chromatography
(silica; eluent: heptane/ethyl acetate=4:1). Yield: 47 g of a
colorless oil (45% yield). The oil crystallized spontaneously upon
standing for 2 days. LC-MS: purity 98%, [M+H]=195.
[0228] With this material available, a Wolf-Kishner reduction
towards 1,3-dimethoxy-5-propylbenzene [4] was performed on 0.5 g
scale. [3] was treated with 2 equivalents of hydrazine in refluxing
ethanol as described for this compound in J. Med. Chem., 1991, 34
(11), p 3310-3316. After 5 hours, a nearly complete conversion into
the desired imine intermediate was observed with LC-MS. All
volatiles were evaporated using a rotary evaporator and the
resulting oil was heated to 230.degree. C. in the presence of KOH
(7.5 eq.) in the melt. After heating for 1 hour, the mixture was
cooled to room temperature overnight. Upon cooling, a white solid
(KOH) with a slightly yellow oil on top was formed. A sample of the
oil was analysed with LC-MS which showed a complete conversion and
exclusive formation of [4].
[0229] The oil was separated from the solids by decanting. The oil
was dissolved in ethyl acetate and washed with 1M aq. HCl. After
drying over Na.sub.2SO.sub.4 and evaporation of the solvents, a
yellow oil was obtained (0.23 g, 49%). Analysis with .sup.1H-NMR
confirmed the structure. Repetition of the reaction on 46 g scale
was performed and a complete conversion was achieved. After aqueous
work-up, [4] was obtained as a yellow oil in moderate yield (21.1
g, 49%) and acceptable purity (93% according to LC-MS) without any
additional purification.
Summary of 1,3-dimethoxy-5-propylbenzene [4]
##STR00067##
[0231] A mixture of 1-(3,5-dimethoxyphenyl)propan-1-one (46 g, 237
mmol) and hydrazine monohydrate (23.71 g, 474 mmol, 23.07 ml) in
ethanol (2.5 ml) was heated to reflux and stirred for 6 hours. All
volatiles were in vacuo using a rotary evaporator to yield a yellow
oil. Potassium hydroxide (100 g, 1776 mmol) was added and heated
the resulting mixture to 230.degree. C. for 30 minutes. The mixture
was allowed to cool to room temperature, dissolved in water (250
mL) and then extracted three times with diethyl ether (3.times.100
mL). The combined organic layers were dried on Na.sub.2SO.sub.4 and
all volatiles were evaporated in vacuo using a rotary evaporator.
Yield: 21.1 g of a yellow oil (49% yield). LC-MS: purity 93%,
[M+H]=181. .sup.1H-NMR .delta. (CDCl.sub.3): 6.35 (d, J=2.2 Hz,
2H), 6.30 (t, J=2.2 Hz, 1H), 3.78 (s, 6H), 2.53 (t, J=7.5 Hz, 2H),
1.63 (sextet, J=7.4 Hz, 2H), 0.94 (t, J=7.3 Hz, 3H).
[0232] With [4] available, a 0.5 g scale test reaction for the
bis-demethylation (based on Molecules, 2014, 19, 13526-13540) was
performed by heating [4] in a melt at 200.degree. C. with pyridine
HCl for 3 hours. A complete conversion was observed on LC-MS and
the desired mass was found in the MS trace. After aqueous work-up,
5-propylbenzene-1,3-diol [5] was isolated as a yellow oil in
moderate yield (0.25 g, 59%) but in good purity (94% according to
LC-MS) without any additional purification. Repetition on 21 g
scale was performed, but the reaction could not be driven to
completion, with 11% of [4] remaining after prolonged heating.
After aqueous work-up, [5] (16.5 g) was obtained with a purity of
only 73% (according to LC-MS). Purification using an automated
Reveleris.RTM. chromatography system (120 g silica cartridge,
heptane:ethyl acetate as eluent) yielded [5] as a yellow oil in
moderate yield (11.6 g, 65%) but high purity (96% according to
LC-MS). The oil spontaneously crystallized upon standing. The
structure of the [5], the C3-olivetol analogue, was confirmed by
.sup.1H-NMR. The preparation of a [5], the C3-olivetol analogue,
starting from commercially available 3,5-dimethoxybenzoic acid, was
performed successfully.
Synthesis of 5-propylbenzene-1,3-diol [5]
##STR00068##
[0234] A mixture of 1,3-dimethoxy-5-propylbenzene (21 g, 117 mmol)
and pyridine hydrochloride (67.3 g, 583 mmol) was heated to
200.degree. C. for 4 hours, then allowed to cool to room
temperature overnight. Water (100 mL) was added and the mixture was
extracted three times with diethyl ether (3.times.100 mL). The
combined organic phase was dried on Na.sub.2SO.sub.4 and all
volatiles evaporated in vacuo using a rotary evaporator.
Un-purified Product yield: 16.5 g brown oil. The brown oil was
purified by column chromatography (120 g silica; eluent:
heptane/ethyl acetate; gradient: t=0 min. 20% ethyl acetate, t=35
min. 50% ethyl acetate). Yield: 11.6 g of a yellow oil (65% yield).
The oil slowly crystallized upon standing. LC-MS: purity 96%,
[M+H]=153. .sup.1H-NMR .delta. (CDCl.sub.3): 6.25 (d, J=2.2 Hz,
2H), 6.18 (t, J=2.2 Hz, 1H), 5.44 (broad s, 2H), 2.45 (t, J=7.4 Hz,
2H), 1.58 (sextet, J=7.4 Hz, 2H), 0.91 (t, J=7.3 Hz, 3H).
Example 3--Generality of Di-Halo Protection of Olivetol
[0235] The use of bromide, chloride and iodide was investigated as
providing di-halo protection to 5-propylbenzene-1,3-diol [5], the
C3-olivetol analogue.
[0236] Adding bromide as protection group: The bromination of [5]
towards 4,6-dibromo-5-propylbenzene-1,3-diol [6] was performed as
shown in FIG. 5. At -30.degree. C., a solution of 0.25 g of [5] in
6 ml DCM was treated with 2.0 eq. of bromine. During cooling of the
initial starting material solution, a sticky oil had formed at the
bottom of the flask which hindered proper stirring. Also, the
bromine was added using a syringe. The low temperature inside the
reaction flask caused the bromine to solidify in the needle and
blocked it. In a subsequent experiment, a bigger stirring magnet
was used and the bromine was added as a solution in DCM using a
dropping funnel in 10 minutes. After stirring for an additional 10
minutes, the reaction mixture was poured into a cold aqueous sodium
thiosulfate solution. A cloudy DCM layer was formed. Addition of
ethyl acetate did not remove the cloudiness. Addition of diethyl
ether resulted in two clear layers. The layers were separated, the
aqueous phase extracted once with diethyl ether. After evaporation
of the solvents, [6] was obtained as an off white solid in moderate
yield (0.40 g, 79%) but in good purity (94%, according to LC-MS).
The mass of the [6] was also found in the mass trace with no mono-
or tri-bromo compound detected. The structure was confirmed by
.sup.1H-NMR and further analysis with HMBC-NMR only showed
interactions between the aromatic proton and aromatic carbons and
not between any aliphatic carbons, thereby confirming the
structure.
[0237] Repetition of the bromination on 1 g scale was performed
using a mechanical top stirrer. After work-up, a second amount of
[6] was obtained in moderate yield (1.67 g, 82%) and analysis by
LC-MS showed that the purity was 93%. Repetition on 10 g scale gave
complete conversion but two impurities were observed in the LC-MS
chromatogram in larger amounts than in earlier experiments.
Nevertheless, this material was used as such in the subsequent
coupling with menthadienol towards compound [7].
Synthesis of 4,6-dibromo-5-propylbenzene-1,3-diol [6]
##STR00069##
[0239] A solution of 5-propylbenzene-1,3-diol (1 g, 6.57 mmol) in
dichloromethane (20 ml) was cooled to -50.degree. C. Initially, a
suspension was formed but upon further cooling, the starting
material precipitated as a sticky oil. Additional DCM (.about.5 mL)
was added to allow for proper stirring. Then, a solution of bromine
(2.111 g, 1.32 mmol, 0.679 ml) in dichloromethane (20 ml) was added
drop wise in 15 minutes using a dosing funnel and the resulting
mixture was stirred for 15 minutes. The temperature was kept below
-50.degree. C. during the reaction and subsequent stirring. The
reaction mixture was poured into a cold (0.degree. C.) solution of
sodium thiosulfate (0.519 g, 3.29 mmol) in water (20 ml) and
stirred vigorously until any bromine color had disappeared. During
stirring, a suspension was formed in the DCM phase. The biphasic
system was extracted with diethyl ether (50 mL) and the layers were
separated. The aqueous phase was extracted once more with diethyl
ether (50 mL) and the combined organic layers were dried on
Na.sub.2SO.sub.4 and all volatiles were evaporated in vacuo using a
rotary evaporator. Yield: 1.67 g off-white solids (82% yield).
LC-MS: purity 96%, [M+H]=309. .sup.1H-NMR .delta. (400 MHz,
CDCl.sub.3): 10.20 (s, 2H), 6.57 (s, 1H), 3.36 (s, 1H), 2.93-2.78
(m, 2H), 2.56-2.44 (m, 2H), 1.57-1.41 (m, 2H), 0.97 (t, J=7.3 Hz,
3H).
[0240] The coupling with menthadienol towards
(1'R,2'R)-3,5-dibromo-5'-methyl-2'-(prop-1-en-2-yl)-4-propyl-1',2',3',4'--
tetrahydro-[1,1'-biphenyl]-2,6-diol [7] was first tested on a 1.6 g
scale, prior to the 10 g scale reaction. [6] was treated with
menthadienol (1.0 eq.) at -30.degree. C. in the presence of
MgSO.sub.4 and p-toluenesulfonic acid in DCM. Conversion into a new
product with the correct mass was observed with LC-MS and by the
addition of extra menthadienol in two portions (0.25 and 0.125
equivalents respectively), the reaction was driven to completion.
After subsequent aqueous work-up and stirring in methanol to
precipitate side products, [7] was isolated as a yellow oil in
quantitative yield (2.36 g, 99%). LC-MS indicated that the purity
was 93% and the structure was confirmed with .sup.1H-NMR.
[0241] Repetition of the coupling with menthadienol on 10 g scale
was performed. The formation of an unknown side product was found
in the final stage of the reaction. After aqueous work-up and
subsequent precipitation of side products in methanol, the isolated
product (22.7 g, 90%) had a purity of only 63% according to LC-MS.
The unknown side product was investigated was an intermediate that
is formed as the reaction proceeds via a rearrangement mechanism.
Treatment with p-toluenesulfonic acid was performed to facilitate
the quantitative conversion of this intermediate towards [7]. A 100
mg sample of the batch was dissolved in DCM and treated with 0.25
equivalents of p-toluenesulfonic acid at 0.degree. C. After
stirring for 4 hours, no conversion was observed with LC-MS. The
mixture was allowed to slowly warm to room temperature and stirred
overnight. LC-MS showed no conversion. The experiment was stopped
and the mixture was discarded.
[0242] To purify the material further, column chromatography over
silica and with heptane/ethyl acetate as eluent was attempted. No
separation was achieved and only baseline material was removed in
this manner. All product containing fractions were collected again
and concentrated to yield 17 g of a dark yellow oil.
[0243] A sample (0.5 g) was subjected to reversed phase column
chromatography (40 g, C18 silica) using a Reveleris.RTM. system and
MeCN/water (with 0.1% formic acid) as eluent. Sufficient separation
of the two main components was achieved and the product containing
fractions were collected and all volatiles evaporated to yield 0.15
g of [7] as a yellow oil. Subsequent analysis showed that the
purity was 99%. The fractions containing the unknown side product
were also combined and concentrated but during this operation, the
material decomposed.
[0244] The entire batch of material was purified using reversed
phase column chromatography in 1.5 g portions using a 120 g C18
silica column and MeCN/water (with 0.1% formic acid) as eluent. In
this manner, 7.7 g (30%) of [7] was obtained as a yellow oil with a
purity of 99% according to LC-MS.
[0245] The fractions containing the unknown side product were
combined and then lyophilized to remove the solvents and to avoid
decomposition. 2.14 g of an off-white solid was obtained.
Subsequent analysis with LC-MS showed that this compound was 92%
with about 7% of [7] as the main impurity. No mass was observed in
the mass trace. Further analysis with .sup.1H-NMR was inconclusive
It is believed that this molecule is comprised of 1 molecule of the
dibromo-n-propylresorcinol and 2 molecules of the menthadienol.
After being exposed to air (after lyophylization), the solid turned
dark purple within 1 hour.
Synthesis of
(1'R,2'R)-3,5-dibromo-5'-methyl-2'-(prop-1-en-2-yl)-4-propyl-1',2',3',4'--
tetrahydro-[1,1'-biphenyl]-2,6-diol [7]
##STR00070##
[0247] A mixture of 4,6-dibromo-5-propylbenzene-1,3-diol (1.67 g,
5.39 mmol), (1R,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol
(0.820 g, 5.39 mmol) and magnesium sulfate (1.621 g, 13.47 mmol) in
dichloromethane (18 mL) was cooled to -35.degree. C. Then,
p-toluenesulfonic acid monohydrate (0.512 g, 2.69 mmol) was added
in one portion and the resulting mixture was stirred at -35.degree.
C. The reaction was monitored with LC-MS and over the course of 5
hours, extra aliquots of
(1R,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (0.205 g, 1.347
mmol and 0.103 g, 0.673 mmol respectively) were added before
allowing the mixture to slowly warm to room temperature overnight.
The reaction mixture was poured into a solution of dibasic
potassium phosphate (0.845 g, 4.85 mmol) in water (18 mL) and the
layers were separated. The aqueous phase was extracted with DCM (18
mL) and the combined organic layers were passed through a phase
separator. Then, all volatiles were evaporated in vacuo using a
rotary evaporator. Un-purified yield: 2.951 g of a yellow oil. The
obtained oil was dissolved in methanol (10 mL) and then stirred for
1 hour at 0.degree. C. The white solid was removed by filtration
using a folded paper filter and was discarded. The clear filtrate
was evaporated to dryness (in vacuo) using a rotary evaporator.
Yield: 2.36 g yellow oil (99% yield). LC-MS: purity 93%, mass not
detected due to poor ionization of the compound. .sup.1H-NMR
.delta. (400 MHz, DMSO-d.sub.6): 8.87-8.21 (m, 2H), 5.15 (s, 1H),
4.45 (d, J=8.7 Hz, 2H), 4.03 (d, J=8.9 Hz, 1H), 3.05-2.93 (m, 1H),
2.88-2.76 (m, 2H), 2.29-2.16 (m, 1H), 2.12-2.08 (m, 1H), 1.99-1.95
(m, 1H), 1.77-1.55 (m, 6H), 1.55-1.42 (m, 3H), 0.96 (t, J=7.3 Hz,
3H).
[0248] Debromination of [7] towards
(1'R,2'R)-5'-methyl-2'-(prop-1-en-2-yl)-4-propyl-1',2',3',4'-tetrahydro-[-
1,1'-biphenyl]-2,6-diol [8], or the desired C3-cannabidiol
derivative, was performed on 0.5 g scale. A mixture of [7],
L-ascorbic acid (0.15 eq.), sodium sulfite (2.65 eq) and
triethylamine in methanol/water was heated to 75.degree. C. for 18
hours. Analysis with LC-MS showed complete conversion but also
showed the formation of several side products. After aqueous
work-up, a brown oil was obtained in good yield (307 mg, 95%) but
the purity was only 73%, according to LC-MS. The oil was purified
by column chromatography using a Reveleris.RTM. system to yield a
purified fraction (72 mg, 22%) as a light yellow brown oil.
Analysis of this material with LC-MS indicated the purity was 96%
and the structure was confirmed by analysis with .sup.1H-NMR.
[0249] Repetition on 1.8 g scale initially yielded 0.46 g product
(39%) as a yellow oil that spontaneously partially solidified.
Analysis with LC-MS showed that the purity was 84%. Further
investigations to the work-up procedure showed that a lot of
product remained in the aqueous phase, which was therefore
extracted with DCM instead of heptane. This treatment furnished a
second amount of material (0.56 g, 48%) as a yellow oil, bringing
the total yield up to 87%.
[0250] Both amounts of [8] were combined and attempts were made to
crystallize the product from heptane, heptane/DCM, heptane/DIPE and
methanol/water mixtures. None of the crystallizations worked. All
material was collected again and purified by column chromatography
using a Reveleris.RTM. system to yield 0.58 g (50%) of [8] as a
light brown oil, which solidified spontaneously upon standing.
Analysis with LC-MS confirmed the mass and showed the purity to be
97%. The structure was confirmed by .sup.1H-NMR. Broad signals in
the aromatic region were observed likely a result of hindered
rotation around the benzylic C--C bond.
[0251] Repetition of the debromination on 7 g scale was carried out
at 40.degree. C. for 2 hours and the mixture was then analyzed with
LC-MS. The partial removal of only 1 bromide group was observed at
this stage. The temperature was increased to 75.degree. C. for 1
hour, which resulted in a nearly complete conversion of the
starting material and the formation of the mono-debrominated
compound. The mixture was then stirred at 75.degree. C. for a
longer period and was monitored over time. After 16 hours, an
almost complete debromination was achieved. The removal of the
second bromine group was more difficult than the first group, but a
full conversion was achieved.
[0252] Aqueous work-up and extraction with DCM yielded 5.1 g of
product as a yellow oil that spontaneously partially solidified.
This material was purified by column chromatography to yield [8]
(3.5 g, 78%) as a slightly yellow oil that spontaneously
solidified. Analysis with LC-MS showed the purity to be 99% and the
correct mass was observed in the mass trace. Further analysis with
.sup.1H-NMR confirmed the structure and showed the presence of 6
w/w % heptane. The analytical data of the prepared compound matched
with the data obtained from a commercial reference sample.
Synthesis of
(1'R,2'R)-5'-methyl-2'-(prop-1-en-2-yl)-4-propyl-1',2',3',4'-tetrahydro-[-
1,1'-biphenyl]-2,6-diol [8]
##STR00071##
[0254] To a solution of
(1'R,2'R)-3,5-dibromo-5'-methyl-2'-(prop-1-en-2-yl)-4-propyl-1',2',3',4'--
tetrahydro-[1,1'-biphenyl]-2,6-diol (1.8 g, 4.05 mmol) in methanol
(15 ml) was added a solution of sodium sulfite (1.353 g, 10.74
mmol) and L-ascorbic acid (0.107 g, 0.608 mmol) in water (15 mL). A
suspension was formed that later formed a sticky oil that hindered
proper stirring. To the suspension, triethylamine (1.476 g, 14.59
mmol, 2.028 ml) was added in one portion which caused the sticky
oil to dissolve just enough to allow proper stirring. The resulting
mixture was heated to 75.degree. C. for 18 hours. After cooling to
room temperature, the reaction mixture was partially concentrated
in vacuo, using a rotary evaporator, to remove most of the methanol
and volatiles. The pH of the remaining aqueous phase was adjusted
to .about.2 with concentrated hydrochloric acid. Heptane (25 mL)
was added and the mixture was stirred for 30 minutes. The layers
were separated, the organic phase was washed with brine (25 mL) and
then evaporated in vacuo using a rotary evaporator. Un-purified
yield: 0.46 g yellow oil. The oil partially solidified
spontaneously. The remaining aqueous phase stirred with DCM (25 mL)
for 30 minutes. The layers were separated, the organic phase was
washed with brine (25 mL) and then evaporated in vacuo using a
rotary evaporator. Un-purified yield: 0.56 g yellow oil. The oil
partially solidified spontaneously. Both oils were combined and
purified by column chromatography (silica, eluent: heptane/ethyl
acetate). Yield: 0.58 g of a light brown oil (50% yield). The oil
solidified upon standing. LC-MS: purity 97%, [M+H]=287. .sup.1H-NMR
.delta. (400 MHz, CDCl.sub.3): 6.27 (s, 1H), 6.17 (s, 1H), 5.98 (s,
1H), 5.57 (s, 1H), 4.70-4.50 (m, 3H), 3.82-3.86 (m, 1H), 2.47-2.34
(m, 3H), 1.87-1.72 (m, 5H), 1.70-1.63 (m, 4H), 1.62-1.52 (m, 3H),
0.90 (t, J=7.3 Hz, 3H).
[0255] The ring-closures of both [7] and [8] towards the C3-THC
analogues [9] and [10], shown in FIG. 5, was performed. Both
ring-closures were screened on 50 mg scale using both [7] and [8]
as the substrate. Table 1 list the results of the screening as
monitored with LC-MS.
TABLE-US-00002 TABLE 1 Overview of ring-closure reactions. #
Substrate Conditions Result 1 7 1 eq. p-TosOH, 17% of a new product
with DCM, rt, 18 h. correct mass 2 7 1 eq. p-TosOH, decomposition
toluene, 100.degree. C., 18 h 3 7 1.2 eq. BF.sub.3 etherate, near
complete conversion into DCM, -10.degree. C., 2 h. new product with
correct mass, some decomposition 4 8 1 eq. p-TosOH, toluene,
decomposition 100.degree. C., 18 h 5 8 1.2 eq. BF.sub.3 OEt.sub.2,
near complete conversion into DCM, -10.degree. C., 2 h. new product
with correct mass, no decomposition
[0256] From these results, it was found that the use of
p-toluenesulfonic acid in toluene at elevated temperature did not
induce an effective ring-closure reaction. At a lower temperature,
however, the use of p-toluenesulfonic acid did lead to the
formation of a new product with the correct mass but only in 17%
estimated yield. Using BF.sub.3 etherate a complete conversion was
achieved with both substrates. These reaction mixtures, e.g., 3 and
5, were subjected to an aqueous work-up and the products were
isolated. In this manner, 28 mg (56% yield) and 39 mg (78% yield)
of [9] and [10] respectively were obtained as yellowish oils.
[0257] Analysis with LC-MS showed the correct masses of [9] and
[10], and purities of 90 and 97%, respectively. The oils were
stored overnight at room temperature. In the case of experiment 3
for [9], the oil had turned dark brown/purple and analysis with
LC-MS showed that the material had decomposed. In the case of
experiment 5 for [10], the oil had partly solidified. Analysis with
.sup.1H-NMR showed that the correct compound was formed but some
impurities, that were not observed with LC-MS, still remained.
[0258] Experiment 5 for [10] was repeated on 1.3 g scale. After 90
minutes of reaction time (at -10.degree. C.), a clean and near
complete conversion was achieved. Aqueous work-up and extraction
yielded the product as a yellow/brownish oil (1.43 g, 102% yield)
with a purity of 96% according to LC-MS. The product was purified
by Reveleris.RTM. column chromatography (using silica and
heptane/ethyl acetate as eluent) to yield a slightly yellow oil
(1.33 g, 95% yield). Analysis with LC-MS showed one main signal in
97% with the correct mass and the other peak originating from
unreacted [8]. Analysis with H-NMR showed several unexpected
signals that indicate that a closely related compound was present
in the obtained material, as well as some residual ethyl acetate.
Further analysis with analytical HPLC revealed that a second
product (22%) was present with a minute difference in retention
time, again indicating that the impurity is closely related to the
product.
[0259] It is known that A9-THC is capable of acid-catalyzed
isomerization to the thermodynamically more stable A8-THC
regio-isomer. The separation of A8- and A9-THC is also known to be
challenging, requiring multiple chromatographic steps. It is
believed that the unknown impurity is the A8-isomer of [10].
Despite the presence of the impurity, the the formation of [10] via
the sequence [7]-[8]-[10] was demonstrated.
Synthesis of
(6aS,10aR)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chro-
men-1-ol [7]-[8]-[10]
##STR00072##
[0261] To a cold (-10.degree. C.) solution of boron trifluoride
etherate (ca. 48% BF.sub.3, 0.833 g, 5.87 mmol, 0.743 mL) in
dichloromethane (20 ml) was slowly added a solution of
(1'R,2'R)-5'-methyl-2'-(prop-1-en-2-yl)-4-propyl-1',2',3',4'-tetrahydro-[-
1,1'-biphenyl]-2,6-diol (1.4 g, 4.89 mmol) in dichloromethane (10
ml) in 15 minutes. After stirring for 90 minutes, the reaction
mixture was quenched by addition of water (20 mL). The formed
slurry was diluted with extra DCM (25 mL) and the layers were
separated. The aqueous phase was extracted once with fresh DCM (25
mL) and the combined organic layers were dried on Na.sub.2SO.sub.4
and all volatiles evaporated in vacuo using a rotary evaporator.
Un-purified yield: 1.42 g yellow/brownish oil. The oil was purified
by column chromatography (80 g silica; eluent: DCM (A)/10% methanol
in DCM (B); gradient: t=0 min. 0% B, t=5 min. 5% B, t=20 min. 20%
B). Yield: 1.33 g slightly yellow oil (95% yield). LC-MS: purity
97%, [M+H]=287. .sup.1H-NMR .delta. (400 MHz, CDCl.sub.3):
6.34-6.23 (m, 2H), 6.17-6.05 (m, 1H), 5.30 (s, 1H), 4.79 (s, 1H),
3.20 (d, J=10.9 Hz, 1H), 2.50-2.37 (m, 2H), 2.23-2.12 (m, 2H),
1.96-1.87 (m, 2H), 1.77-1.64 (m, 4H), 1.64-1.49 (m, 2H), 1.45-1.36
(m, 3H), 1.09 (s, 2H), 0.91 (t, J=7.3 Hz, 3H).
[0262] The ring-closure via compound [9] followed by removal of the
two bromides to form compound [10] was performed. To avoid the
observed stability issues, compound [9] was not isolated but used
directly as a solution in DCM. A solution of compound [7] (200 mg)
in DCM was treated with 1.2 equivalents of BF.sub.3 etherate at
-10.degree. C. LC-MS showed the formation of a new product (the
mass of compounds [7] and [9] are the same and thus gives no
additional information about the conversion at this point). After a
total reaction time of 45 minutes, the mixture was quenched with
water and the layers were separated. The organic phase was used as
such in the debromination-reaction.
[0263] After the addition of methanol, an aqueous solution of
Na.sub.2SO.sub.3 (2.65 eq.) and L-ascorbic acid (0.15 eq.) was
added, followed by triethylamine (3.6 eq.). The mixture was heated
to 40.degree. C. and the conversion was monitored by LC-MS. After 2
hours at this temperature, no conversion was observed. The
temperature was increased to 75.degree. C. and the mixture was
stirred for 1 hour. Again, no significant conversion was detected.
Stirring was continued overnight and subsequent analysis with LC-MS
showed the formation of a new product with the correct retention
time and mass of [10]. After aqueous work-up, 85 mg of a yellow oil
was obtained (65% yield over two steps, not corrected for the
purity) with a purity of 78%. The formation of [10] via the
sequence [7]-[9]-[10] was demonstrated.
Synthesis of
(6aS,10aR)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chro-
men-1-ol [10]
##STR00073##
[0265] To a cold (-10.degree. C.) solution of boron trifluoride
etherate (ca. 48% BF.sub.3, 77 mg, 0.540 mmol, 0.068 ml) in
dichloromethane (2 mL) was slowly added a solution of
(1'R,2'R)-3,5-dibromo-5'-methyl-2'-(prop-1-en-2-yl)-4-propyl-1',2',3',4'--
tetrahydro-[1,1'-biphenyl]-2,6-diol (200 mg, 0.450 mmol) in
dichloromethane (2 ml) in 15 minutes. After stirring for 60
minutes, the reaction was quenched by addition of water (2 mL). The
formed slurry was diluted with extra DCM (2 mL) and the layers were
separated using a phase separator. To the organic phase was added
methanol (2 mL) and a solution of sodium sulfite (150 mg, 1.193
mmol) and L-ascorbic acid (11.89 mg, 0.068 mmol) in water (2 mL).
At room temperature, added triethylamine (164 mg, 1.621 mmol, 0.225
ml) in one portion, heated the mixture to 75.degree. C. and stirred
overnight. After cooling to room temperature, the reaction mixture
was partially concentrated in vacuo, using a rotary evaporator, to
remove most of the methanol and volatiles. The pH of the remaining
aqueous phase was adjusted to .about.4 with 3M aq. hydrochloric
acid. DCM (5 mL) was added and the mixture was stirred for 30
minutes. The layers were separated and remaining aqueous phase was
extracted with DCM (5 mL). The layers were separated and the
combined organic phases were dried with a phase separator. All
volatiles were evaporated in vacuo using a rotary evaporator.
Yield: 85 mg yellow oil (66% yield). LC-MS: purity 78%, [M+H]=287.
.sup.1H-NMR .delta. (400 MHz, CDCl.sub.3): 6.34-6.23 (m, 2H),
6.17-6.05 (m, 1H), 5.30 (s, 1H), 4.79 (s, 1H), 3.20 (d, J=10.9 Hz,
1H), 2.50-2.37 (m, 2H), 2.23-2.12 (m, 2H), 1.96-1.87 (m, 2H),
1.77-1.64 (m, 4H), 1.64-1.49 (m, 2H), 1.45-1.36 (m, 3H), 1.09 (s,
2H), 0.91 (t, J=7.3 Hz, 3H).
[0266] Adding chloride as protection group: The chlorination of
olivetol towards cannabidiol was performed as shown in FIG. 6. A
solution of olivetol (1 g) in DCM was treated with 2 equivalents of
sulfuryl chloride using a dropping funnel at 0.degree. C. After 1
hour, a new product with the correct mass was formed, as well as a
large amount of mono-chlorinated material. The starting material
was no longer detected by LC-MS. The reaction was continued in time
and small aliquots of sulfuryl chloride were added to drive the
reaction to completion. After the addition of 3 equivalents of
sulfuryl chloride in total, a small amount of the tri-chloro
compound was also formed. No work-up was performed in this
experiment.
[0267] The reaction was repeated on 1 g scale. The sulfuryl
chloride (2.25 equivalents) was slowly dosed into the reaction
mixture in a controlled manner using a syringe pump. A second
aliquot of sulfuryl chloride (0.5 equivalent) was added to drive
the reaction to ca. 95% conversion. After aqueous work-up, a
yellowish oil was obtained that spontaneously solidified. A quick
purification by column chromatography resulted in the complete
removal of the remaining 5% mono-chlorinated compound and [11] was
obtained as a colorless oil (0.88 g, 64%) that spontaneously
solidified. Analysis with LC-MS showed the purity to be >95% and
confirmed the mass of the intended product. Analysis with 1H-NMR
confirmed the structure.
[0268] The synthesis was repeated on 25 g scale and a complete
conversion was achieved. After aqueous work-up, the obtained brown
oil (31.1 g) was dissolved in heptane (100 mL) and stored at
4.degree. C. overnight, which resulted in the formation of white
crystals. These were filtered off and dried on the filter to yield
[11] (22.4 g, 65% yield and 98% purity according to LC-MS). The
structure was confirmed with .sup.13C-APT-NMR spectroscopy.
Synthesis of 4,6-dichloro-5-pentylbenzene-1,3-diol [11]
##STR00074##
[0270] To a cold (0.degree. C.) solution of
5-pentylbenzene-1,3-diol (25 g, 139 mmol) in dichloromethane (250
ml) was slowly added sulfuryl chloride (46.8 g, 347 mmol, 28.1 ml)
over a 30 minute period. The resulting mixture was stirred over
night while slowly warming to room temperature. The reaction
mixture was quenched with 1M aq. NaOH (150 mL) and subsequently
stirred for 15 minutes. The formed slurry was diluted with extra
DCM (100 mL) and then acidified to pH .about.3 with 3M aq. HCl. The
layers were separated and the aqueous phase was extracted once with
DCM (150 mL). The combined organic layers were dried on
Na.sub.2SO.sub.4 and all volatiles evaporated in vacuo using a
rotary evaporator. Un-purified 31.1 g brown/yellow oil. The oil was
dissolved in heptane (100 mL) and stored the solution at 4.degree.
C. The formed crystals were filtered off and then dried on filter
by air stream. Yield: 22.4 g slightly yellow solid (65% yield).
LC-MS: purity 98%, [M-H]=247. .sup.1H-NMR .delta. (400 MHz,
CDCl.sub.3): 6.62 (s, 1H), 5.61 (s, 2H), 2.90-2.81 (m, 2H),
1.62-1.50 (m, 2H), 1.45-1.31 (m, 4H), 0.92 (t, J=7.0 Hz, 3H).
[0271] The coupling with menthadienol towards
(1'R,2'R)-3,5-dichloro-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-
-tetrahydro-[1,1'-biphenyl]-2,6-diol [12] was investigated on 1 g
scale. Using the same conditions as used for the bromide-analogue,
[11] was coupled with menthadienol (1 equivalent) at -35.degree. C.
using p-toluenesulfonic acid (0.5 eq.). The reaction was monitored
with LC-MS and two further aliquots of menthadienol were added (0.3
and 0.15 eq.) over the course of 4 hours. A mixture of starting
material (22%), product (56%) and a possible intermediate (22%) was
obtained. The reaction was then allowed to slowly warm to room
temperature overnight. Upon warming, an unknown product (50%) was
formed presumably the already ring-closed product, analogous to the
bromide. The remainder of the mixture was mainly product (42%).
[0272] The experiment was repeated on 1 g scale and the reaction
was monitored carefully over time. Again, several aliquots of
menthadienol were added. After a total reaction time of 5 hours,
the reaction was still incomplete. After aqueous work-up and
subsequent purification by column chromatography to remove the
unreacted material, 1.06 g of [11] was obtained as a colorless oil
(66% yield) with a purity of >98% according to LC-MS.
Synthesis of
(1'R,2'R)-3,5-dichloro-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-
-tetrahydro-[1,1'-biphenyl]-2,6-diol [12]
##STR00075##
[0274] A mixture of 4,6-dichloro-5-propylbenzene-1,3-diol (1 g,
4.52 mmol), (1R,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol
(0.689 g, 4.52 mmol) and magnesium sulfate (1.361 g, 11.31 mmol) in
dichloromethane (10 mL) was cooled to -35.degree. C. Then,
p-toluenesulfonic acid monohydrate (0.430 g, 2.262 mmol) was added
in one portion and the mixture was stirred for 90 minutes. A second
aliquot of (1R,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol
(0.207 g, 1.357 mmol) was added and the mixture was stirred for 90
minutes. A third aliquot of
(1R,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (0.103 g, 0.678
mmol was added and the mixture was stirred for 5.5 hours. A fourth
aliquot of (1R,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol
(0.103 g, 0.678 mmol) was added and the mixture was stirred for 90
minutes. The reaction mixture was quenched by pouring into a
solution of dibasic potassium phosphate, (0.709 g, 4.07 mmol) in
water (10.0 mL). The layers were separated with a phase separator
and the organic phase was evaporated in vacuo using a rotary
evaporator. The obtained oil was stirred in methanol (5 mL) at
0.degree. C. for 1 hour, then all undissolved solids were filtered
off using a folded paper filter. Un-purified yield: 1.06 g almost
colorless oil. The oil was purified by column chromatography (120 g
silica; eluent: heptane (A)/ethyl acetate (B); gradient: t=0 min.
0% B, t=25 min. 10% B). Yield: 0.44 g colorless oil (27% yield).
LC-MS: purity 100%, [M-H]=381. .sup.1H-NMR .delta. (400 MHz,
CDCl.sub.3): 6.39 (s, 1H), 5.60 (s, 1H), 5.46 (s, 1H), 4.53 (s,
1H), 4.42 (s, 1H), 4.08-3.98 (m, 1H), 2.90-2.75 (m, 2H), 2.62-2.51
(m, 1H), 2.31-2.16 (m, 1H), 2.14-2.03 (m, 1H), 1.87-1.72 (m, 5H),
1.68 (s, 3H), 1.60-1.46 (m, 2H), 1.44-1.29 (m, 4H), 0.91 (t, J=6.9
Hz, 3H).
[0275] For the dechlorination step, [11] was used as a model
compound since only a limited amount of [12] was obtained. The same
conditions for the debromination (Na.sub.2SO.sub.3 (2.65 eq.),
L-ascorbic acid (0.15 eq.), triethylamine (3.6 eq.), a
methanol/water mixture, 75.degree. C.) were applied on [11] on 250
mg scale. After stirring for 1 hour, no conversion was observed.
After stirring overnight, some decomposition was observed.
[0276] The dechlorination step was repeated using the same scale
and conditions but using 2-propanol instead of methanol. The
reaction temperature was increased to 100.degree. C. No conversion
was achieved after stirring overnight. No decomposition was
detected after reacting overnight.
[0277] The dechlorination step was repeated using triethylsilane
mediated, Pd.sub.2(d-t-bppf)Cl.sub.2 catalyzed reaction conditions
as described in Tet. Lett., 2013, 54, 4518-4521. A degassed
solution of [11] (250 mg) in dioxane was treated with
triethylsilane (5 eq.), triethylamine (2 eq.) and
Pd.sub.2(d-t-bppf)Cl.sub.2 (5 mol %). After stirring for 1 hour at
100.degree. C., near complete conversion into a new product was
observed with LC-MS. After aqueous work-up, the newly formed
product could not be isolated nor detected in significant amounts
in either the organic or aqueous phase.
[0278] [12] was used for the dechlorination step. A solution of
compound [12] (100 mg) in dioxane was treated with triethylsilane
(5 eq.), triethylamine (2 eq.) and Pd.sub.2(d-t-bppf)Cl.sub.2 (5
mol %). After stirring at 100.degree. C. overnight, partial
conversion into a new product was observed with LC-MS with 36%
starting material remaining, 44% of a new and unknown product and
only 6% of a product with the correct retention time of the fully
dechlorinated cannabidiol). The compounds did not ionize properly
on the LC-MS systems and no useful mass traces were obtained.
[0279] The removal of the chloride protection groups was tested by
catalytic hydrogenation. A solution of [11] (60 mg) in methanol (1
mL) was treated with palladium on carbon (5 mg, 10% metal loading)
under hydrogen atmosphere at ambient pressure. After stirring for 2
hours, partial conversion into a new product was observed with
LC-MS but no mass was observed in the mass trace. After stirring
overnight a complete conversion was achieved. Subsequent filtration
to remove the catalyst and evaporation of the solvent yielded 40 mg
of a yellowish oil. Analysis with .sup.1H-NMR revealed that the
characteristic protons of the double bond were no longer present
and also no increase in the number of aromatic signals was
found.
[0280] Adding iodide as protection group: The iodination of
olivetol towards cannabidiol was performed as shown in FIG. 7.
Olivetol (100 mg) was treated with N-iodosaccharin (2.1
equivalents) in MeCN at room temperature. After stirring overnight,
a complete conversion was observed with LC-MS and the correct mass
was found in the mass trace but several unknown other signals were
observed as well, one of them presumably being the saccharine
residue.
[0281] After evaporation of the solvent in vacuo and subsequent
trituration in methanol to remove most of the solid saccharin
residue, the obtained clear filtrate was evaporated in vacuo to
yield 234 mg of an orange/red oil that still contained some solids.
This material was further purified by Reveleris.RTM. column
chromatography using silica and heptane/ethyl acetate as eluent to
yield a colorless oil (108 mg, 45% yield) that solidified upon
scratching with a spatula. Analysis with LC-MS showed the purity to
be >98% and the structure was confirmed with .sup.1H-NMR.
[0282] Repetition of the synthesis of
4,6-diiodo-5-pentylbenzene-1,3-diol [13] on 1.25 g scale was
performed. After evaporation of the solvent in vacuo and subsequent
trituration in methanol to remove most of the solid saccharin
residue, the obtained clear filtrate was evaporated in vacuo and
then further purified by Reveleris.RTM. column chromatography using
silica and heptane/ethyl acetate as eluent to yield a colorless oil
(1.70, 57% yield), which solidified spontaneously. Analysis with
LC-MS showed the purity to be 97%.
Synthesis of 4,6-diiodo-5-pentylbenzene-1,3-diol [13]
##STR00076##
[0284] A mixture of 5-pentylbenzene-1,3-diol (1.25 g, 6.94 mmol)
and N-iodosaccharin (4.50 g, 14.56 mmol) in acetonitrile
(anhydrous, 12.5 mL) was stirred overnight (in darkness). All
volatiles were evaporated in vacuo using a rotary evaporator and
the obtained residue was stirred in a minimal amount of methanol
overnight. The undissolved material was filtered off and the
filtrate was evaporated in vacuo using a rotary evaporator. The oil
was purified by column chromatography (120 g silica; eluent:
heptane (A)/ethyl acetate (B); gradient: t=0 min. 1% B, t=5 min. 1%
B, t=30 min. 5% B). Yield: 1.70 g colorless oil (57% yield). The
oil solidified spontaneously. LC-MS: purity 98%, [M-H]=430.
.sup.1H-NMR .delta. (400 MHz, CDCl.sub.3): 6.56 (s, 1H), 5.94 (s,
1H), 5.39 (s, 1H), 2.71-2.57 (m, 2H), 1.64-1.47 (m, 2H), 1.46-1.23
(m, 4H), 1.00-0.81 (m, 3H).
[0285] The reaction of [13] with menthadienol was performed on 100
mg scale. After multiple additions of menthadienol, increasing the
temperature to 40.degree. C. and stirring overnight, a large amount
of [13] was found by LC-MS and the mass of
(1'R,2'R)-3,5-diiodo-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-t-
etrahydro-[1,1'-biphenyl]-2,6-diol [14] was not detected in the
mass trace. The reaction was repeated with 1 equivalent of p-Tos-OH
(compared to the normal 0.5 eq.) but no conversion was seen.
[0286] Different Lewis acids were screened on 50 mg scale. Glass
vials were charged with iodide [13] (50 mg), magnesium sulfate (3
eq.) and the Lewis acid to be tested (1 eq.). The vials were placed
in a pre-cooled reaction block at -35.degree. C. A pre-cooled
solution of menthadienol (2 eq.) in dichloromethane (1 mL) was
added to each vial. The vials were stirred at -35.degree. C. for 2
hours and samples (20 uL) were taken from each vial and
subsequently analysed with HPLC. Table 2 lists the results. No
conditions were found to couple [13] with menthadienol. Di-iodide
is found to be not reactive toward menthadienol.
TABLE-US-00003 TABLE 2 Overview of Lewis acid screening. Lewis acid
Results Lithium chloride No conversion Nickel(II)chloride No
conversion Copper(II)chloride No conversion Copper(I)chloride No
conversion Zinc chloride No conversion Iron(II)chloride No
conversion Iron(III)chloride No conversion Manganese(II)chloride No
conversion Cerium(III)chloride No conversion Cobalt(II)chloride No
conversion Indium(III)chloride No conversion Bismuth(III)chloride
No conversion Samarium(III)chloride No conversion
[0287] Overall, 5-propylbenzene-1,3-diol (the C3-olivetol analogue)
prepared in Example 2 was successfully di-halo protected using
bromide protection groups. Using the bromide protection groups both
(1'R,2'R)-5'-methyl-2'-(prop-1-en-2-yl)-4-propyl-1',2',3',4'-tetrahydro-[-
1,1'-biphenyl]-2,6-diol (the C3-cannabidiol-analogue) and
(6aS,10aR)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chro-
men-1-ol (the C3-THC analogue) were prepared with two different
synthetic pathways demonstrated for the C3-THC analogue. The
syntheses proceeded similarly to the C5-isomer. The synthesis of
dichloro-olivetol and diiodo-olivetol using the C5-isomer was also
performed successfully. Subsequent coupling with menthadienol was
successful for the dichloro-olivetol, but not for the
diiodo-olivetol.
Example 4--Reaction of Dibromo-Olivetol with Other Olefins
[0288] The coupling of dibromo-olivetol with other olefins was
performed. Dibromo-olivetol was coupled with the compounds in FIG.
8, including cyclohexene, octane, cyclohex-2-enol and linalool. A
mixture of dibromo-olivetol (250 mg), the olefin to be coupled (1
eq.), magnesium sulfate (2.5 eq.) in DCM (2.5 mL) was treated with
p-Tos-OH (0.5 eq.) at room temperature. After stirring for 2 hours,
no conversion was observed with LC-MS, except for the experiment in
which cyclohex-2-enol was used as coupling partner.
[0289] Using cyclohex-2-enol, full conversion into a new product
was observed. After a simple aqueous work-up, the experiment with
cyclohex-2-enol as coupling partner yielded 223 mg of a brownish
oil with a purity of 94% according to LC-MS. In the mass trace, a
mass of [M-H]=417 was found. Combined with the structural data
obtained from the .sup.1H-NMR spectrum it is believed that the
formed compound is
(S)-3,5-dibromo-4-pentyl-1',2',3',4'-tetrahydro-[1,1'-biphenyl]-2,6-diol,
the structure of which is shown in FIG. 9.
[0290] The coupling of dibromo-olivetol with linalool was repeated
using THF as solvent so that a higher reaction temperature could be
achieved. The amount of p-Tos-OH was also reduced to 0.1 eq. to
prevent potential side reactions and/or decomposition. LC-MS
indicated formation of a new product with still 47% starting
material remaining after reacting overnight at 65.degree. C. After
aqueous work-up, the starting material was recovered with a purity
of 73% according to LC-MS.
[0291] The coupling of dibromo-olivetol (C5-analogue) with
different olefins has proven feasible. The coupling of
dibromo-olivetol, and related compounds, can be performed using a
cyclic olefin containing a double bond and a hydroxy-group at a
conjugated position. In some embodiments, the olefin can be any
olefin as described herein, provided the olefin is not cyclohexene,
octane, linalool or combinations thereof.
Synthesis of
3,5-dibromo-4-pentyl-1',2',3',4'-tetrahydro-[1,1'-biphenyl]-2,6-diol
##STR00077##
[0293] To a mixture of 4,6-dibromo-5-pentylbenzene-1,3-diol (0.25
g, 0.740 mmol), cyclohex-2-enol (0.073 g, 0.740 mmol) and magnesium
sulfate (0.223 g, 1.849 mmol) in dichloromethane (2.5 ml) was added
p-toluenesulfonic acid monohydrate (0.070 g, 0.370 mmol) in one
portion at room temperature. The resulting mixture was stirred
overnight and then quenched with a solution of dibasic potassium
phosphate, (0.116 g, 0.666 mmol) in water (2.5 ml). The layers were
separated with a phase separator and the organic phase was
evaporated in vacuo using a rotary evaporator. Yield: 223 mg
brownish oil (69% yield). LC-MS: purity 94%, [M-H]=417. .sup.1H-NMR
.delta. (400 MHz, CDCl.sub.3): 6.48-5.92 (m, 3H), 5.83 (d, J=10.0
Hz, 1H), 4.13-4.03 (m, 1H), 2.99-2.87 (m, 2H), 2.21-2.09 (m, 2H),
2.01-1.82 (m, 2H), 1.79-1.62 (m, 2H), 1.61-1.49 (m, 2H), 1.48-1.32
(m, 4H), 0.93 (t, J=7.0 Hz, 3H).
Example 5--Synthesis of
(1R,2R,4S)-2-(dimethylamino)-1-methyl-4-(prop-1-en-2-yl)cyclohexan-1-ol
##STR00078##
[0295] To a solution of (-)-limonene oxide (39.73 g, 261 mmol) in
ethanol (70 mL) was added a 40% solution of dimethylamine in water
(62.3 g, 553 mmol, 70 mL). The mixture was heated to 65.degree. C.
and stirred for 26 hours. A clear yellow solution was formed. The
mixture was allowed to cool to room temperature and all volatiles
evaporated in vacuo using a rotary evaporator. The mixture was
taken up in MTBE (90 mL) and washed with water (30 mL). The
solution was then dried over Na.sub.2SO.sub.4, filtered and the
residue washed with MTBE (20 mL). To the resulting solution was
slowly added a solution of oxalic acid (10.28 g, 114 mmol) in
acetone (40 mL) forming a thick white precipitate which required
mechanical stirring. The precipitate was heated to reflux for 30
min. After cooling to room temperature and stirring for 2 hours the
precipitate was filtered and the residue washed with MTBE (100 mL).
The resulting white hydroscopic solid was transferred back into the
reaction vessel and suspended in 30 mL ethanol. The suspension was
heated to reflux forming a yellow emulsion. MTBE (150 mL) was added
dropwise forming a white precipitate. The suspension was allowed to
cool to room temperature and stirred overnight. The suspension was
filtered and washed twice with MTBE:ethanol (4:1, 50 mL). The
resulting white solid was dissolved in water (71 mL) and MTBE (55
mL). Under vigorous stirring a 2N solution of KOH was added (130
mL). The phases were separated, the organic phase was dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. Yield: 20.96 g of a
colourless oil (40.7% yield). GCMS: purity 98.9%, [M]=197.
Example 6--Synthesis of
(1R,4S)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-en-1-ol
(1R,4S-menthadienol)
##STR00079##
[0297] A solution of
(1R,2R,4S)-2-(dimethylamino)-1-methyl-4-(prop-1-en-2-yl)cyclohexan-1-ol
(24.68 g, 125 mmol) in ethanol (50 mL) was heated to reflux. Upon
reaching reflux a solution of hydrogen peroxide (17.76 g, 157 mmol,
30%) was added dropwise. After complete addition the mixture was
refluxed for 2.5 hours. After cooling to room temperature the
reaction was quenched by addition of sodium sulfite (5.12 g, 40.6
mmol) in water (18 mL). After a peroxide teststrip revealed no
peroxides were present the reaction mixture was diluted with
acetone (60 mL) resulting in a white suspension. The precipitate
was removed by filtration and the residue washed with acetone (60
mL). Concentration in vacuo using a rotary evaporator resulted in
30.05 g of the N-oxide as a yellow oil. The N-oxide was transferred
to a Kugelrohl flask and subsequently pyrolyzed at 160 C at 15 mBar
pressure. The clear oil slowly turned orange and after complete
removal of solvents solidified to an orange solid which melted upon
further heating. A clear oil was collected which was dissolved in
MTBE (60 mL) and washed with water (16 mL) followed by washing with
a cooled solution of 1% sulfuric acid (1.times.16 mL, 2.times.10
mL). The organic phase was then washed with satd. NaHCO.sub.3
solution (2 mL), subsequently dried over Na.sub.2SO.sub.4 and
concentrated in vacuo using a rotary evaporator. Yield: 15.15 g of
a colourless oil (80% yield). GCMS: purity 95%, [M]=152. Chiral
HPLC: enantiomeric excess 99%.
Example 7--Synthesis of
(1'S,2'S)-3,5-dibromo-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'--
tetrahydro-[1,1'-biphenyl]-2,6-diol
##STR00080##
[0299] A mixture of 4,6-dibromo-5-pentylbenzene-1,3-diol (16.2 g,
43.6 mmol), (1R,4S)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-en-1-ol
(4.35 g, 28.6 mmol) and magnesium sulfate (15 g, 125 mmol) in
dichloromethane (100 mL) was cooled to -30.degree. C. Then,
p-toluenesulfonic acid monohydrate (4.19 g, 22.03 mmol) was added
in one portion and the resulting mixture was stirred at -30.degree.
C. The reaction was monitored with LCMS and over the course of 5
hours, extra aliquots of
(1R,4S)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-en-1-ol (4.26 g, 27.9
mmol and 1.95 g, 12.8 mmol respectively) were added before stirring
the mixture at -30.degree. C. The reaction mixture was poured into
a solution of dibasic potassium phosphate (7.60 g, 43.6 mmol) in
water (150 mL) and the layers were separated. The aqueous phase was
extracted with DCM (40 mL) and the combined organic layers were
concentrated to dryness in vacuo using a rotary evaporator. The
obtained oil was dissolved in methanol (150 mL) and then stirred
for 1.5 hours at -15.degree. C. A white solid was removed by
filtration and was discarded. The filtrate containing the product
was used as is in the next reaction step. LCMS: purity 77%,
[M+H]=471.
Example 8--Synthesis of
(1'S,2'S)-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydro-[-
1,1'-biphenyl]-2,6-diol
##STR00081##
[0301] To a solution of
(1'S,2'S)-3,5-dibromo-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'--
tetrahydro-[1,1'-biphenyl]-2,6-diol (assumed 20.59 g, 43.6 mmol) in
methanol (180 ml) was added a solution of sodium sulfite (15.92 g,
126 mmol) and L-ascorbic acid (1.24 g, 0.608 mmol) in water (150
mL). A yellow suspension was formed, triethylamine (17.42 g, 172
mmol, 24 ml) was added in one portion. The resulting mixture was
heated to 70.degree. C. for 22 hours, subsequently 62 g of solvent
were removed by disstillation at 90.degree. C. After cooling to
room temperature the pH of the remaining aqueous phase was adjusted
to .about.4 with concentrated hydrochloric acid. Heptane (40 mL)
was added and the mixture was stirred for 30 minutes. The layers
were separated, the organic phase was washed with brine (20 mL) and
dried over Na.sub.2SO.sub.4. The resulting brown solution was
cooled to -20.degree. C. in attempts to crystallize the material.
After several attempts at cooling, further concentration and
recooling. A sample was cooled on dry ice under vigorous
scratching, forming white crystals. These were used to seed the
remaining solution which immediately crystallized. Yield: 7.65 g of
off-white crystals (55% yield). LCMS: purity 99.3%, [M+H]=315.
Chiral HPLC: enantiomeric excess 99%. .sup.1H-NMR .delta. (400 MHz,
CDCl.sub.3): 6.40-6.10 (br, 2H), 6.00 (br, 1H), 5.57 (s, 1H), 4.79
(br, 1H), 4.65 (s, 1H), 4.55 (s, 1H), 3.90-3.10 (m, 1H), 2.46-2.36
(m, 3H), 2.29-2.17 (m, 1H), 2.14-2.05 (m, 1H), 1.87-1.71 (m, 5H),
1.66 (s, 3H), 1.55 (p, J=7.6 Hz, 2H), 1.37-1.22 (m, 4H), 0.87 (t,
J=7.0 Hz, 3H).
[0302] While this disclosure has been particularly shown and
described with reference to example embodiments thereof, it will be
understood by those skilled in the art that various changes in form
and details may be made therein without departing from the scope of
the invention encompassed by the appended claims.
* * * * *